Patent Application
20240317867
This application contains a Sequence Listing in computer readable form, submitted via USPTO Patent Center. The entire contents of the XML file entitled “IPM0120US3_Sequence_Listing.xml” created on Jun. 3, 2024, having a size of 28,912 bytes is incorporated herein by reference.
The insulin/insulin-like growth factors (IGFs) constitute a network of ligands, cell-surface receptors, and binding proteins involved in the regulation of multiple physiological and pathological processes. Insulin/IGFs play key developmental and metabolic roles at every stage of life. Insulin/IGF signaling also contributes to regulation of lifespan, while dysregulation of signaling has been implicated in neoplasia. Although the insulin receptor (InsR) and IGF-1 receptor (IGF1R) share the majority of their downstream cytoplasmic mediators, most experimental and clinical evidence is consistent with the notion that InsR activation (mainly by insulin) leads primarily to metabolic activities, whereas IGF1R activation (mainly by IGF-1 or IGF-2) leads to proliferative and differentiative events (Sarfstein R and Werner H Endocrinology. 2013 May; 154(5):1672-9; Siddle K J Mol Endocrinol. 2011 Jun. 17; 47(1):R1-10).
InsR and IGF1R belong to a family of transmembrane tyrosine kinase-containing receptors. In their mature form, they present as heterotetramers composed of 2 extracellular α-subunits and 2 transmembrane β-subunits harboring the tyrosine kinase activity. Both IGF- and insulin receptors show a high degree of homology (84% in the tyrosine kinase domain, 45%-65% in the ligand binding domain, and above 50% in overall amino acid sequence). In addition, the receptors display a remarkable similarity in genomic organization (Sarfstein R and Werner H, loc. cit.; Arnalez F and Helman L. Hematol Oncol Clin North Am. 2012 June; 26(3):527-42).
There are also “hybrid” receptors composed of half an insulin receptor and half an IGF receptor (IRαβ linked to IGF1Rαβ). Hybrids bind IGFs with similar affinity to IGFR, but bind insulin with substantially lower affinity than InsR. It is unclear whether hybrid receptors have a distinct physiological role (Sarfstein R and Werner H, loc. cit.; Arnalez F and Helman L., loc. cit).
The insulin receptor exists in two splice variant isoforms as a result of alternative splicing of the sequence encoded by exon 11; the ‘B’ isoform recognizes only insulin, but the ‘A’ isoform, which is the isoform that is most commonly expressed by tumours, recognizes both insulin and IGF1 and 2. Both isoforms are differentially expressed during development, with InsR-A predominantly ex-pressed in fetal tissues and InsR-B predominately expressed in adult tissues, particularly liver, muscle, and adipocytes. The IGF1R displays an opposite pattern of expression, being absent in liver and present at low levels in adipose tissue and at high levels in brain. In addition, and consistent with its potent anti-apoptotic, pro-survival role, the IGF1R is overexpressed in most tumors and malignant cells (Pollak M Nat Rev Cancer. 2012 Feb. 16; 12(3):159-69, Sarfstein R and Werner H, loc. cit.; Siddle K, loc. cit).
IGF1 and IGF2 can be expressed in endocrine, paracrine or autocrine manners, the latter being common in transformed cells. The liver is their main site of production. By contrast, insulin production is confined to pancreatic β-cells. Insulin and the IGFs bind with high affinity to their specific receptor and with lower affinity to the non-cognate receptor, with the exception of IGF2, which also binds InsR-A with high affinity (Pollak M, loc cit.; Siddle K, loc. cit.).
Ligand binding induces conformational changes in the structures of the InsR and IGF1R and activates their intrinsic tyrosine kinase activity. Although insulin and IGFs play distinct physiological roles, they utilize the same signaling pathways. Downstream signaling of the InsR and IGF1R is mostly channeled through the MAPK/Ras-Raf-Erk pathway, the phosphatidylinositol-3-kinase/AKT/mTOR (PI3K/AKT) pathway and the Janus kinase/signal transducer and activator of transcription (JAK/STAT) pathway. Ultimately, activation of IGF1R results in increased cell proliferation and decreased apoptosis, whereas activation of the InsR by insulin-binding promotes the storage and synthesis of lipids, protein, and carbohydrates and inhibits their breakdown and release into the circulation. The first step by which insulin increases energy storage or utilization involves the regulated transport of glucose into the cell, mediated by the facilitative glucose transporter Glut4 (Chang et al. Mol Med. 2004 July-December; 10(7-12):65-71.). Insulin expression is confined to specialized pancreatic β-cells, and under normal circumstances it is tightly regulated by the level of circulating glucose. Insulin-stimulated glucose uptake by classic insulin-sensitive organs (liver, muscle and adipose tissue) reduces circulating glucose levels. The β-cells are thus glucose ‘thermostats’, sensing glucose and releasing insulin to maintain physiologic glucose levels within a relatively narrow range. Breakdown of the delicately balanced InsR signaling pathways results in an uncontrolled or impaired insulin-secretion, dysregulated blood glucose levels, and eventually to pancreatic β cell destruction or loss-of-function, a condition commonly known as diabetes (Pollak M, loc cit.; Siddle K, loc. cit.; Sarfstein R and Werner H, loc. cit; Arnalez F and Helman L., loc. cit)
Diabetes mellitus, affecting 8.3% of the adult population of the world and increasing at an alarming rate, is one of the most common diseases of current era. The number of diabetes mellitus patients is projected to increase from 382 million in 2013 to 592 million by 2035, denoting a net increase of 55%. The predominant form is type 2 diabetes (T2D) which accounts for nearly 90% of all diabetes cases (Hameed et al. World J Diabetes. 2015 May 15; 6(4):598-612).
Type 1 diabetes (T1D) is an autoimmune disorder afflicting millions of people worldwide and occurs as a consequence of the organ-specific immune destruction of the insulin-producing β-cells in the islets of Langerhans within the pancreas. Once those cells are destroyed, patients with type 1 diabetes lose blood glucose control, which can result in both acute conditions (for example, ketoacidosis and severe hypoglycaemia) and secondary complications (including heart disease, blindness and kidney failure). Type 1 diabetes is thought to develop as a consequence of a combination of genetic predisposition, largely unknown environmental factors, and stochastic events, however, the precise immunologic, genetic and physiologic events that control disease initiation and progression continue to be elucidated.
Early type 2 diabetes (T2D) is caused by insulin resistance of classic insulin-target organs (i.e. reduced uptake of glucose by normal insulin-target cells, often induced by excess calorific intake) leading to hyperinsulinaemia. Initially, these increased levels of insulin are sufficient to overcome insulin resistance and to avoid hyperglycemia. However, hyperglycemia eventually occurs not only because of increasing insulin resistance but also because of decreasing insulin output by pancreatic β-cells.
Controlling blood glucose levels is the major goal of diabetes treatment. T1D is commonly managed with administration of insulin as well as dietary changes and exercise. However, the life-long requirement of insulin injections after nutritional intake may severely reduce quality of life of the patient. Moreover, appropriate dosage and timing of insulin injection can prove difficult. Cure or prevention of T1D is severely impaired by the absence of biomarkers that are reliably correlated with the pathogenic process, resulting in β-cell numbers being markedly reduced at the time of diagnosis. The goal of most clinical trials in type 1 diabetes today is to improve functional residual β-cell mass, optimally through induction of immunologic tolerance, while preserving protective immune responses. By definition, this will rarely “cure” the disease because of the significant β-cell destruction that preceded the treatment. Therefore, reliable biomarkers preferably expressed at disease onset would be highly desirable. Other methods focus on the transplantation of either the pancreas or pancreatic β-cells to reconstitute the insulin-secreting function. However, this technique is hampered by a shortage of donor organs. For T2D, besides insulin, other non-insulin therapeutics including synthetic blood sugar lowering agents are available, which are however often limited in terms of their practical effect, convenience of administration, and may elicit adverse reactions.
The safety concerns and adverse effects of available diabetes therapeutics, as well as the lack of permanent remission of disease with any agent tested to date have heightened interest in specific interventions that might modulate the disease.
It is the object of the invention to comply with the needs in the prior art.
The present inventors observed that the protein encoded by the human KIAA1324L gene, also known as estrogen-induced gene 121 protein (EIG121L) (Uniprot: A8MWY0), strongly co-localizes with the protein encoded by the human KIAA1324 gene, also known as estrogen-induced gene 121 protein (Uniprot: Q6UXG2), which in turn co-localizes with IGF-1R, IGF-2R and InsR, in particular in the pancreas as described in PCT/EP2016/071126. However, nothing was known, let alone speculated about a role of KIAA1324 or KIAA1324L in metabolism, let alone cancer. This role was for the first time attributed to said proteins by the present inventors.
Due to its domain structure that resembles that of IGFRs, the present inventors assigned to the protein (KIAA1324L/EIG121L) a function of a receptor and thus they called the protein IGFR-like receptor 2 (IGFR-I2; as shown in SEQ ID NO: 2, for example encoded by a nucleotide sequence as shown in SEQ ID NO: 1), while the protein to which IGFR-I2 is co-localized (KIAA1234/Q6UXG2); as described in PCT/EP2016/071126, is referred to herein as IGFR-like receptor 1 (IGFR-I1; as shown in SEQ ID NO. 4, for example encoded by a nucleotide sequence as shown in SEQ ID NO: 3).
In line with a previous invention as described in PCT/EP2016/071126, the present inventors elucidated that either knocking down or knocking-out IGFR-like receptor 1 results in increased phosphorylation of InsR/IGF-1R as well in increased phosphorylation of AMPK, a downstream signaling component that becomes active when either IGFRs or InsR or both transmit a signal, e.g., binding of insulin. Hence, IGFR-like receptor 1 seems to negatively regulate InsR and/or IGF-1R-mediated signaling. Also, with their knowledge of their previous invention, i.e., that the protein encoded by the KIAA1324 gene (IGFR-I1) acts indeed as an IGFR-like receptor, the present inventors, by inspecting genome wide association studies (GWAS), found a strong association of SNPs in the KIAA1324 gene with type 2 diabetes, LDL cholesterol and/or coronary artery disease.
In sum, the protein encoded by the human KIAA1324 gene (IGFR-I1) which the present inventors assigned a function of a modulator of IGF-1R and/or InsR, plays a role in metabolism, in particular in insulin signaling and also likely in LDL cholesterol metabolism as well as in attending ills such as coronary heart disease. This finding was of outstanding importance, since it was not believed that apart from IGFRs and InsR, there may be a further player in insulin signaling. Due to its presumed negative regulatory function on IGFRs and/or InsR (see
The inventors of the present invention now found that the protein described herein, IGFR-I2, strongly co-localizes and endogenously interacts with the previously described IGFR-I1 (see
Accordingly, in context with the present invention, IGFR-I2 appears to be a target for treating medical conditions associated with metabolic disorders such as, e.g., diabetes, particularly type 1 diabetes, type 2 diabetes, gestational diabetes, prediabetes, insulin resistance, metabolic syndrome, and impaired glucose tolerance. Such treatment may be accomplished by antibodies directed against IGFR-I2 or antibodies directed against the interaction surface or positions between IGFR-I1 and IGFR-I2. Also, given the role of EIG121 (IGFR-I1) in cancer (e.g., endometrial cancer, gastric cancer, breast cancer, prostate cancer, lung cancer, brain cancer (in particular pituitary gland cancer) and others), the co-localization and binding ability of IGFR-I2 to IGFR-I1 identifies IGFR-I2 as target molecule in the treatment of cancer. In context with the present invention, such treatment of cancer may be achieved by antagonists or agonists of IGFR-I2, depending on the role IGFR-I1 plays in different cancer types, i.e. either a cancer activating (proliferation) effect, or a cancer inhibiting effect, respectively.
Also, antagonists or agonists of IGFR-I2 open up new and urgently needed possibilities to revert, e.g. insulin resistance as commonly seen in diabetes mellitus type II pathogenesis or to block insulin signaling. Strikingly, the present inventors could also previously show that the IGFR-like receptor 1 is associated with β cell de-differentiation in the pancreas, an early event in disease onset that ultimately leads to β cell destruction or loss-of-function. Hence, the IGFR-like receptor 2 which strongly co-localizes with IGFR-I1 and seems to negatively regulate InsR and/or IGFR-mediated signaling may also be a promising diagnostic tool enabling early diagnosis and/or treatment of diabetes before irrevocable loss of β cells, thereby potentially paving the way for the treatment of diabetes mellitus type I.
Accordingly, the present invention provides an isolated DNA sequence encoding an IGF receptor (IGFR)-like receptor 2 which is capable of reacting with antibodies raised against an IGFR-like receptor 2 of SEQ ID No: 2 (amino acid sequence IGFR-I2), wherein said antibodies preferably specifically bind to said IGFR-like receptor 2 of SEQ ID NO: 2.
In particular, said antibodies specifically bind to the extracellular domain of said IGFR-like receptor 2 of SEQ ID NO: 2. The extracellular domain is assumed to encompass the region between amino acid positions 48 to 929 of SEQ ID NO: 2.
In particular, said isolated DNA sequence may encode an IGFR-like receptor 2 comprising a sequence corresponding to SEQ ID No. 2. The isolated DNA sequence may in particular comprise a sequence corresponding to SEQ ID No. 1 (cDNA IGFR-I2).
Further provided herein is a vector comprising the DNA sequence as described herein. Said vector may further comprise a gene regulation element operatively linked to the DNA sequence encoding said IGFR-like receptor 2 of SEQ ID NO: 2. A host cell comprising said vector is also envisaged.
Further provided herein are binding agents capable of specifically binding an IGFR-like receptor 2, said IGFR-like receptor 2 comprising a sequence corresponding to sequence SEQ ID No. 2 for use as a diagnostic marker for diabetes or the risk of developing diabetes.
In embodiments, provided herein is a binding agent which specifically binds to an IGFR-like receptor 2 epitope, wherein said binding agent of the IGFR-like receptor 2 comprises complimentary determining regions (CDRs): CDR-H1: SGYYWN (SEQ ID NO:6), CDR-H2: YISYDGTIYYNPSLKN (SEQ ID NO:7), CDR-H3: RLGY (SEQ ID NO:8), CDR-L1: KSSQSLLNSGNQKNYLT (SEQ ID NO:10), CDR-L2: WASTKES (SEQ ID NO:11), and CDR-L3: QNDYRYPFT (SEQ ID NO:12).
In some embodiments, a binding agent including these CDR sequences can be used as a diagnostic marker, such as for diabetes or the risk of developing diabetes. In other embodiments, a binding agent including these CDR sequences can be used in an in vitro method to identify other factors that associate with the IGFR-like receptor 2. In other embodiments, a binding agent including these CDR sequences can be used in a method for the treatment or prevention of a medical condition.
Antagonists and agonists of the IGFR-like receptor 2 of the invention, said IGFR-like receptor 2 comprising for example a sequence corresponding to SEQ ID No. 2, are also provided herein. Said antagonists and agonists are in general envisaged for use as a medicament. Specifically, the antagonists and agonists provided herein are intended for use in a method of prophylactic and/or therapeutic treatment of cancer, e.g., endometrial cancer, gastric cancer, breast cancer, prostate cancer, lung cancer, brain cancer (in particular pituitary gland cancer) or of metabolic and endocrine disorders such as, e.g., diabetes. Antagonists are however preferred, particularly for treating metabolic disorders such as diabetes. The antagonist can be a binding agent having the CDRs: CDR-H1 of SEQ ID NO:6; CDR-H2 of SEQ ID NO:7, CDR-H3 of SEQ ID NO:8, CDR-L1 of SEQ ID NO:10, CDR-L2 of SEQ ID NO:11, and CDR-L3 of SEQ ID NO:12. Such antagonist can be used for the referenced prophylaxis and/or therapy.
The binding agent with the referenced CDRs can be part of a modified antibody or fragment thereof, and can include one or more of non-antibody derived sequence(s). For example, the binding agent with the CDRs can be in the form of a fusion protein or a modified light and or heavy chain polypeptide, or a fragment thereof, that includes the non-antibody derived sequence(s). In some embodiments, the binding agent includes the CDRs: CDR-H1 of SEQ ID NO:6; CDR-H2 of SEQ ID NO:7, CDR-H3 of SEQ ID NO:8, CDR-L1 of SEQ ID NO:10, CDR-L2 of SEQ ID NO:11, and CDR-L3 of SEQ ID NO:12, and a cell penetrating peptide (CPP) sequence. For example, the binding agent can include the recited CDRs and a CPP sequence of any one of SEQ ID NO:13 (Pep-1), SEQ ID NO:14 (TAT), SEQ ID NO:15 (Pepth), SEQ ID NO:16 (aurein 1.2), SEQ ID NO:17 (MTS), or SEQ ID NO:18 (GFWFG), with SEQ ID NO: 13 (Pep-1) or SEQ ID NO: 15 (Pepth) being preferred.
In embodiments, the binding molecule including CDRs and CPP sequences are used for the treatment or prevention of a medical condition in a subject. The method includes administering the binding agent to a subject, wherein the binding molecule is internalized into a target cell via clathrin-mediated endocytosis (CME) and can cross cellular membranes via the CPP sequence and become present in the cytoplasm. In the method, the binding molecules with the CPP sequence enter the cells via CME, escapes from endosomes and translocates into the cytoplasm via the CPP sequence, and intracellularly binds to the cytoplasmic domain of IGFR-L2 and prevents its CME, since the relatively short cytoplasmic domain binds to the adaptor protein complex (AP2) which is required for clathrin-mediated endocytosis. This will lead to prolonged plasma membrane retention of IGFR-L2 and block its function to desensitize receptor tyrosine kinases (RTKs), as IGFR-L1 and L2 facilitate internalization of these via CME and thus switch off the RTK signal.
The antagonists and agonists are envisaged to bind specifically to said IGFR-like receptor 2 of SEQ ID NO: 2 and may be selected from inter alia an antibody, a siRNA, a nucleic acid, an aptamer, a peptide, a protein, or a small molecule organic compound etc. The antibody may be a monoclonal or polyclonal antibody, for example a monoclonal antibody.
In particular, said antibody, which is preferably a monoclonal antibody, may be an antibody (e.g. a monoclonal antibody) specifically binding to an epitope of said IGFR-like receptor 2, for example said epitope being located within the extracellular domain of IGFR-I2 (SEQ ID NO: 2).
The present invention also provides a method of generating an antibody against an epitope of IGFR-like receptor 2 of SEQ ID NO: 2. The antibody can be prepared by a method including the following steps: (a) administering to a mammal an antibody-generating peptide from an IGFR-like receptor 2 as set forth in SEQ ID NO: 2, and (b) purifying the antibody.
In the diagnostic and/or therapeutic uses provided herein, diabetes is envisaged to comprise type 1 diabetes, type 2 diabetes, gestational diabetes, prediabetes, insulin resistance, metabolic syndrome, and impaired glucose tolerance.
Treatment with the antagonist or agonist of IGFR-like receptor 2 of SEQ ID NO. 2, antagonists being preferred, may prevent or reverse insulin resistance and/or reverse de-differentiation and/or loss-of-function of pancreatic β-cells.
For therapeutic uses to treat cancers as provided herein, antagonists or agonists to IGFR-I2 may be used, e.g., which effect reduction of proliferation and/or induction of apoptosis of cancer cells.
Further provided herein is a medicament or a pharmaceutical composition comprising an antagonist or agonist of IGFR-like receptor 2 (antagonists being preferred). In a preferred embodiment said IGFR-like receptor 2 comprises or consists of a sequence corresponding to SEQ ID No. 2. Said antagonist or agonist is in a preferred embodiment a monoclonal antibody that specifically binds to said IGFR-like receptor 2. In embodiments, the medicament or a pharmaceutical composition includes the binding agent having the CDRs: CDR-H1 of SEQ ID NO:6; CDR-H2 of SEQ ID NO:7, CDR-H3 of SEQ ID NO:8, CDR-L1 of SEQ ID NO:10, CDR-L2 of SEQ ID NO:11, and CDR-L3 of SEQ ID NO:12, and one or more CPP sequence of any one of SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17, or SEQ ID NO:18.
In other embodiments, the diagnostic composition includes the binding agent having the CDRs: CDR-H1 of SEQ ID NO:6; CDR-H2 of SEQ ID NO:7, CDR-H3 of SEQ ID NO:8, CDR-L1 of SEQ ID NO:10, CDR-L2 of SEQ ID NO:11, and CDR-L3 of SEQ ID NO:12, optionally for use in a method of diagnosing diabetes or the risk of developing diabetes.
Said preferably monoclonal antibody is in particular envisaged to bind to an epitope of said IGFR-like receptor 2 within its extracellular domain.
Further provided herein is an antibody, preferably a monoclonal antibody which specifically binds to IGFR-like receptor 1 and/or 2, thereby interrupting interaction of IGFR-I1 and IGFR-I2.
Further provided herein is an in vitro screening assay for antagonists or agonists of an IGFR-like receptor 2, said method comprising the steps of:
Also provided herein is an IGFR-like receptor 2 antagonist or agonist obtainable by the in vitro screening assay, said IGFR-like receptor 2 antagonist or agonist being selected from an antibody, a siRNA, a nucleic acid, an aptamer, a peptide, a protein, or a small molecule organic compound.
The present invention also relates to the use of the binding agents of the invention and in particular of the antibodies of the invention for the in vitro detection of degeneration of pancreatic islet cells. The use of these antibodies for the preparation of a therapeutic or diagnostic composition is also contemplated.
Further provided herein is a method of treating diabetes, comprising administering an IGFR-like receptor 2 antagonist or agonist to a subject, said IGFR-like receptor 2 comprising a sequence corresponding to SEQ ID No. 2.
Further provided herein is a method of treating cancer (e.g., endometrial cancer, gastric cancer, breast cancer, prostate cancer, lung cancer, brain cancer (in particular pituitary gland cancer)), comprising administering an IGFR-like receptor 2 antagonist or agonist to a subject, said IGFR-like receptor 2 comprising a sequence corresponding to SEQ ID No. 2.
The method of treatment of diabetes or cancer can use a binding agent having the CDRs: CDR-H1 of SEQ ID NO:6; CDR-H2 of SEQ ID NO:7, CDR-H3 of SEQ ID NO:8, CDR-L1 of SEQ ID NO:10, CDR-L2 of SEQ ID NO:11, and CDR-L3 of SEQ ID NO:12 and one or more CPP sequence of any one of SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17, or SEQ ID NO:18.
The invention will be better understood with reference to the detailed description when considered in conjunction with the non-limiting examples and the accompanying drawings. The figures illustrate embodiments of methods of the invention. The patent or application file contains at least one drawing executed in color. Copies of this patent or patent application with color drawing(s) will be provided by the Office upon request and payment of the necessary fee.
The present inventors have surprisingly discovered a novel IGFR-like receptor 2 (IGFR-I2) which is strongly co-localized to and endogenously interacts with a previously described IGFR-like receptor 1 (IGFR-I1; KIAA1234; EIG122), the latter is expressed adjacent to IGF-1, IGF-2 and Insulin ligands in the pancreas, and demonstrated to negatively regulating InsR and/or IGF1R-mediated signaling. In this regard the present inventors surprisingly figured out that downregulation or knockout of IGFR-like receptor 2 leads to modulation (up- and downregulation) of IGFR-like receptor 1 levels, suggesting that IGFR-like 2 regulates internalization, degradation or recycling of IGFR-like 1. Additionally, knocking down or knocking-out IGFR-like receptor 2 leads to upregulation of IR and IGF1R by phosphorylation of InsR and IGF1R, as well as to increased phosphorylation of Akt, a downstream signaling component that becomes active when either IGFRs or InsR or both transmit a signal, e.g. binding of insulin. Hence, as already described for IGFR-like receptor 1 in PCT/EP2016/071126, also IGFR-like receptor 2 seems to negatively regulate InsR and/or IGFR-mediated signaling, thereby affecting metabolism and/or growth (proliferation). Therefore, antagonists and agonists of IGFR-I2 open up new and urgently needed possibilities to revert insulin resistance as commonly seen in diabetes pathogenesis or to block insulin signaling. Also, the present inventors could previously also show that the IGFR-like receptor 1 is associated with β cell de-differentiation in the pancreas, an early event in disease onset that ultimately leads to β cell destruction or loss-of-function. Hence, the IGFR-like receptor 2 as described in context with the present invention may also be a promising diagnostic tool enabling early diagnosis and treatment of diabetes before irrevocable loss of β cells.
The present inventors previously pioneered in elucidating the function of the human KIAA1324 gene in encoding an IGFR-like receptor 1 as described herein. The protein product of KIAA1324 previously referred to as UPF0577 protein KIAA1324 or Estrogen-induced gene 121 (EIG121) protein has commonly been known as a cancer marker and further identified the pivotal role of IGFR-I1 in metabolism to the protein. Thus, the newly identified interaction partner of IGFR-I1 as described herein, namely IGFR-I2, also appears to play a decisive role in conditions associated with IGFR-I1, i.e. cancer as well as metabolism as described herein.
In a first aspect, the invention thus provides an isolated DNA sequence encoding an IGF receptor (IGFR)-like receptor 2 which is capable of reacting with antibodies raised against an IGFR-like receptor 2 of SEQ ID No: 2, wherein said antibodies specifically bind to said IGFR-like receptor 2 of SEQ ID NO. 2
In particular, said isolated DNA sequence is envisaged to encode protein KIAA1324L with Uniprot Acc. No. A8MWY0, the amino acid sequence as shown in SEQ ID No.: 2 or a functional variant thereof, said proteins also referred to as “IGFR-like receptor 2” or “IGFR-I2” herein.
Importantly, expression of the “EIG121” gene (IGFR-I1) which strongly co-localizes or interacts with/binds to IGFR-I2 as shown in context with the present invention was known for its role in neoplastic proliferations (particularly cancer) associated with estrogen excess and was previously also identified to be a target for antagonists or agonists to treat metabolic disorders such as diabetes.
Functional variants of the IGFR-like receptor 2 disclosed herein, which have a threshold sequence identity or sequence homology to the IGFR-like receptor described herein, are also encompassed by the term “IGFR-like receptor 2” or “IGFR-I2”. Said functional variants are envisaged to have at least 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 97%, 98%, 99%, 99.5% or 100% sequence identity with SEQ ID No.: 2 and are capable of reacting with antibodies raised against an IGFR-like receptor 2 of SEQ ID No: 2, wherein said antibodies specifically bind to said IGFR-I2, preferably to an epitope within the extracellular domain thereof.
It is further envisioned that said functional variants preferably exhibit the same properties as IGFR-I2, i.e. interact or bind to IGFR-I1 as shown herein and in the examples and inhibit or reduce InsR and/or IGF1R-mediated signaling, in particular Akt phosphorylation and/or phosphorylation of other downstream signaling components that become active when either IGFRs or InsR or both transmit a signal. The term “% identity” or “% sequence identity” as used herein refers to the percentage of pair-wise identical residues—following (homologous) alignment of a sequence of a polypeptide of the invention with a sequence in question—with respect to the number of residues in the longer of these two sequences. Percent identity is determined by dividing the number of identical residues by the total number of residues and multiplying the product by 100. The term “homology” is used herein in its usual meaning and includes identical amino acids as well as amino acids which are regarded to be conservative substitutions (for example, exchange of a glutamate residue by an aspartate residue) at equivalent positions in the linear amino acid sequence of two proteins. Preferably, the amino acid sequence shown in SEQ ID NO:2 is preferred as a “reference sequence”. The term “reference sequence” and “wild type sequence” (of the IGFR-like receptor 1 or 2) is used interchangeably herein.
As used herein, the term “binding” or “interacting” in context with binding or interaction between IGFR-I2 and IGFR-I2 means strong co-localization as shown and described herein, or may also refer to the formation of dimers (dimerization), e.g., the formation of heterodimers of IGFR-I2 and IGFR-I1. In context with the present invention, such binding can be shown, e.g., by applying co-immunoprecipitation assays as shown and described herein, where (monoclonal) antibodies are directed to IGFR-I1, thereby also allowing “pulling down” or staining of IGFR-I2 (see, e.g.,
Binding agents of the disclosure, such as those including CDR sequences of SEQ ID NOs:6-12, can include one or more of non-antibody derived amino acid sequence(s). A non-antibody derived amino acid sequence(s) can be covalently or non-covalently attached to the binding agent with the CDRs of the disclosure. If the non-antibody derived amino acid sequence(s) is covalently attached, it can be attached via a peptidic linkage, a non-peptidic linkage, or can be fused in frame to one or more amino acids of the binding agent. For example, in a polypeptide including the CDRs, the non-antibody derived amino acid sequence(s) can be placed at one or more of the N-terminus, the C-terminus, or/and at a position within the polypeptide (i.e., between the N- and C-termini). The non-antibody derived amino acid sequence(s) can be in the form of a terminal tag and can be used for purification or detection of the binding agent.
In some embodiments binding agents of the disclosure include a cell penetrating peptide (CPP) sequence. CPPs can promote entry of the binding molecule into the cell by promoting cross-membrane transport of the binding agent. Exemplary CPPs include Pep-1, TAT, Pepth, aurein 1.2, MTS, and GFWFG, which are shown in Table 3. See, for example, Zhao, Y., et al. (2003) MTS-conjugated-anti-active caspase 3 antibodies inhibit actinomycin D-induced apoptosis. Apoptosis 8, 631-637; Gupta, B., et al. (2005) Intracellular delivery of large molecules and small particles by cell-penetrating proteins and peptides. Adv Drug Deliv Rev. 57, 637-651. 25; Bechara, C. & Sagan, S. (2013) Cell-penetrating peptides: 20 years later, where do we stand? FEBS Lett 587, 1693-1702; Morris, M. C., et al. (2001) A peptide carrier for the delivery of biologically active proteins into mammalian cells. Nat Biotechnol 19, 1173-1176; Cohen-Saidon, C. et al. (2003) A novel strategy using single-chain antibody to show the importance of Bcl-2 in mast cell survival. Blood 102, 2506-2512; Arrouss, I. et al. (2013) Specific targeting of caspase-9/PP2A interaction as potential new anti-cancer therapy. PLoS One 8, e60816; Zhao, Y., et al. (2001) Chemical engineering of cell penetrating antibodies. J Immunol Methods 254, 137-145; and Lonn, P., et al. (2016) Enhancing Endosomal Escape for Intracellular Delivery of Macromolecular Biologic Therapeutics. Sci Rep 6, 32301.
For example, the binding agent with the CDRs can be in the form of a modified light and or heavy chain polypeptide that includes one or more CPP(s), or a fragment thereof. In some embodiments, the binding agent includes the CDRs: CDR-H1 of SEQ ID NO:6; CDR-H2 of SEQ ID NO:7, CDR-H3 of SEQ ID NO:8, CDR-L1 of SEQ ID NO:10, CDR-L2 of SEQ ID NO:11, and CDR-L3 of SEQ ID NO:12, and a cell penetrating peptide (CPP) sequence. For example, the binding agent can include the recited CDRs and a CPP sequence of any one of SEQ ID NO:13 (Pep-1), SEQ ID NO:14 (TAT), SEQ ID NO:15 (Pepth), SEQ ID NO:16 (aurein 1.2), SEQ ID NO:17 (MTS), or SEQ ID NO:18 (GFWFG).
One or more CPP(s) can be associated with a light chain (LC), a heavy chain (CH), or both a LC and a HC of the binding agent having the CDRs of SEQ ID NOs: 6-12, wherein the CPP(s) is or are attached by covalent or non-covalent attachment(s) to the LC, HC, or both. In particular embodiments, one or more CPP(s) is, or are, fused in frame to one or more amino acids of the binding agent, such as fused in from to the LC and/or the HC of the binding agent. For example, a CPP is fused to the C-terminus of the LC, is inserted into the sequence of the HC before the hinge region of the HC, is inserted into the sequence of the HC after the hinge region, or any combination thereof. In one preferred aspect, a CPP is fused to the C-terminus of the LC, and is also inserted into the sequence of the HC before or after the hinge region. Fusion of the one or more CPP(s) to the identified locations of the LC and/or HC does not affect the functionality of the binding agent at all, or to any significant amount.
In some embodiments, the binding agent includes a LC sequence and a CPP of any one of SEQ ID NOs:13-18 attached to the C-terminus of the light chain sequence. For example, the binding agent can include CDR-L1 of SEQ ID NO:10, CDR-L2 of SEQ ID NO:11, and CDR-L3 of SEQ ID NO:12, and a LC sequence that has 50% or greater, 60% or greater, 70% or greater, 80% or greater, 90% or greater, 95% or greater, 97% or greater, 98% or greater, or 99% or greater sequence identify to the portions of SEQ ID NO: 9 that are outside of the CDR-L1, -L2, and -L3 sequences, with any one of SEQ ID NOs:13-18 attached to the C-terminus of said light chain sequence.
In some embodiments, the binding agent includes a HC sequence and a CPP of any one of SEQ ID NOs:13-18 inserted (a) between two adjacent amino in proximity to, or at, the amino end (before) of the hinge region, (b) between two adjacent amino acids in proximity to, or at, the carboxyl end (after) the hinge region, or both (a) and (b).
The hinge region of the heavy chain is a flexible stretch of amino acid stretch between the CH1 and CH2 domains of the IgG and IgA immunoglobulin classes. The hinge region functions to link two heavy chains by disulfide bonds. Hinge regions are characterized by a core stretch of amino acids including cysteine (C) and proline (P) residues. The hinge region can be divided into three regions in an N to C-terminal direction: the upper hinge, core hinge, and lower hinge. A core hinge region sequence is CPPCP (SEQ ID NO:21) as found in human IgG1 heavy chain molecules. An upper hinge and core hinge sequence is DKTHTCPPCP (SEQ ID NO:22).
Accordingly, the binding molecules of the disclosure can include the sequence [one of SEQ ID NOs:13-18]-[SEQ ID NO:21], [SEQ ID NO:21]-[one of SEQ ID NOs:13-18], [one of SEQ ID NOs:13-18]-[HC—CH1/hinge-SEQ]-[SEQ ID NO:21], or [SEQ ID NO:21]-[HC—CH2/hinge-SEQ]-[one of SEQ ID NOs:13-18], wherein HC—CH1/hinge-SEQ represents up to 25, up to 20, up to 15, up to 10, up to 5, or 4, 3, 2, or 1 amino acid residue(s) of the heavy chain (CH1 domain/upper hinge region) that are N-terminal to (before) the hinge core sequence, and wherein HC—CH2/hinge-SEQ represents up to 25, up to 20, up to 15, up to 10, up to 5, or 4, 3, 2, or 1 amino acid residue(s) of the heavy chain (CH2 domain/lower hinge region) that are C-terminal to (after) the hinge core sequence.
For example, the binding agent can include CDRs: CDR-H1 of SEQ ID NO:6; CDR-H2 of SEQ ID NO:7, CDR-H3 of SEQ ID NO:8, and a HC sequence that has 50% or greater, 60% or greater, 70% or greater, 80% or greater, 90% or greater, 95% or greater, 97% or greater, 98% or greater, or 99% or greater sequence identify to the portions of SEQ ID NO: 5 that are outside of the CDR-H1, -H2, and -H3 sequences, with any one of SEQ ID NOs:13-18 inserted (a) between two adjacent amino in proximity to, or at, the amino end (before) of the hinge region, (b) between two adjacent amino acids in proximity to, or at, the carboxyl end (after) the hinge region, or both (a) and (b).
SEQ ID NO: 20 represents an exemplary sequence human IgG1 heavy chain constant region sequence including the hinge region, where the CPPs can be inserted before or after the core hinge sequence, for example, between CH1/upper hinge region and the core hinge region, in the CH1/upper hinge region proximal to the core hinge region, between CH2/lower hinge region and the core hinge region, or in the CH2/lower hinge region proximal to the core hinge region, or any combination thereof. For example, with the CPPCP hinge core sequence spanning from positions 109-113 of SEQ ID NO: 20, any of SEQ ID NOs:13-18 is (a) inserted between two adjacent amino acids within positions 84-109, 89-109, 94-109, 99-109, or 105-109 of SEQ ID NO: 20, (b) is inserted between two adjacent amino acids within positions 113-138, 113-133, 113-128, 113-123, 113-118 of SEQ ID NO: 20, or both (a) and (b). In some embodiments, the binding molecule comprises a HC sequence as a framework for the CDRs: CDRs-H1-H3 (SEQ ID NOs:6-8), wherein the HC sequence has 50% or greater, 60% or greater, 70% or greater, 80% or greater, 90% or greater, 95% or greater, 97% or greater, 98% or greater, or 99% or greater sequence identity to SEQ ID NO: 20.
SEQ ID NO: 20 is a non-silenced human heavy chain IgG1 sequence, including CH1, hinge, CH2, and CH3 domains. Alternatively, a silenced heavy chain sequence that has mutations that prevent engagement of the heavy chain with the immune system can be used, wherein the silenced heavy chain provides a framework for the incorporated CDRs. See, for example, Vafa, O., et al. (2014) Methods, 65: 114-126. Preferably, in some methods of the disclosure, if the binding molecule comprises CH domains, it comprises a non-silenced heavy chain sequence.
In vivo, a binding agent having the CDRs of the disclosure and one or more CPP(s) enters the cell and becomes available intracellularly via the CPP sequence(s). The binding agent can then prevent the internalization of IGFR-L2, since the relatively short cytoplasmic domain binds to the adaptor protein complex (AP2) and is therefore internalized via clathrin-mediated endocytosis. In the cytoplasm, a binding agent with the CDR and CPP sequences binds to the relatively small cytoplasmic domain of IGFR-L2, which in turn blocks AP2 interaction and thus interaction with the CME machinery is prevented, leading to prolonged plasma membrane retention. As a result of this interaction, this prevents the receptor tyrosine kinases from being rapidly desensitized, as IGFR-L1 and L2 internalize these via CME and thus switch off the signal.
The percentage of sequence homology or sequence identity can, for example, be determined herein using the BLASTP, version blastp 2.2.5 (Nov. 16, 2002; cf. Altschul, S. F. et al. (1997) Nucl. Acids Res. 25, 3389-3402). In this embodiment the percentage of homology is based on the alignment of the entire polypeptide sequences (matrix: BLOSUM 62; gap costs: 11.1) including the propeptide sequences, preferably using the wild type protein scaffold as reference in a pairwise comparison. It is calculated as the percentage of numbers of “positives” (homologous amino acids) indicated as result in the BLASTP program output divided by the total number of amino acids selected by the program for the alignment.
In the context of the invention, the expression “position corresponding to another position” (e.g., regions, fragments, nucleotide or amino acid positions, or the like) is based on the convention of numbering according to nucleotide or amino acid position number and then aligning the sequences in a manner that maximizes the percentage of sequence identity. Because not all positions within a given “corresponding region” need be identical, non-matching positions within a corresponding region may be regarded as “corresponding positions.” Accordingly, as used herein, referral to an “amino acid position corresponding to amino acid position [X]” of a specified protein sequence represents, in addition to referral to amino acid positions of the specified protein sequence, referral to a collection of equivalent positions in other recognized protein and structural homologues and families. The same may be applied to the expression “sequence corresponding to sequence”, mutatis mutandis. I.e., the referral to a sequence “corresponding to” a specified protein sequence [X], in addition to referral to sequence the specified protein sequence, referral to a collection of equivalent sequences in other recognized protein and structural homologues and families.
The term “InsR” or “IR” refers to the insulin receptor and generally comprises both the IR-A (also known as “isoform short”) and IR-B (also known as “isoform long”) isoforms. The InsR occurs as a tetramer of 2α chains carrying the insulin-binding regions and 2β chains carrying the kinase domain, linked by disulfide bonds. The InsR is a receptor tyrosine kinase that is activated by binding of insulin, IGF-1 and IGF-2, ultimately leading to signaling through the MAPK/Ras-Raf-Erk pathway, the phosphatidylinositol-3-kinase/AKT/mTOR (PI3K/AKT) pathway and/or the Janus kinase/signal transducer and activator of transcription (JAK/STAT) pathway. More precisely, ligand binding to the α-chains of the InsR ectodomain induces structural changes within the receptor leading to autophosphorylation of various tyrosine residues within the intracellular tyrosine kinase domain of the β-chain, leading to recruitment and phosphorylation of several intracellular substrates, including, insulin receptor substrates (IRS1, 2, 3, 4), SHC, GAB1, CBL and other signaling intermediates. Each of these phosphorylated proteins serve as docking proteins for other signaling proteins that contain Src-homology-2 domains (SH2 domain), including the p85 regulatory subunit of PI3K and SHP2. Phosphorylation of IRSs proteins leads to the activation of two main signaling pathways: the PI3K-AKT/PKB pathway, which is responsible for most of the metabolic actions of insulin, and the Ras-MAPK pathway, which regulates expression of some genes and cooperates with the PI3K pathway to control cell growth and differentiation. Binding of PI3K to phosphotyrosines on IRS1 leads and subsequent PI3K activation leads to the phosphorylation and activation of AKT, AMPK and mTOR, a signaling pathway which regulates metabolism and integrates signals from insulin. InsR activation upon ligand binding also triggers the Ras/RAF/MAP2K/MAPK pathway via phosphorylation of IRS1 and recruitment of GRB2/SOS, which is mainly involved in mediating cell growth, survival and cellular differentiation of insulin.
An illustrative example of the InsR is the human InsR with Uniprot Acc. No. P06213 (entry version 216 of Jul. 22, 2015) and variants thereof. Insulin receptors in the context of the present invention are preferably capable of inducing (i) Akt phosphorylation, and/or (ii) AMPK phosphorylation and/or (iii) mTOR phosphorylation upon binding of their ligand, in particular insulin.
The term “IGF-receptor 1” or “IGF1R” or “IGFRI” is used herein to refer to the Insulin-like growth factor 1 receptor tyrosine kinase. IGF1R binds to IGF1 with high affinity and IGF2 and insulin (INS) with a lower affinity. Ligand binding activates the receptor kinase, leading to receptor autophosphorylation, and phosphorylation of multiple substrates, including, the insulin-receptor substrates (IRS1/2), Shc and 14-3-3 proteins, which ultimately leads to the activation of three main signaling pathways: the PI3K-AKT/PKB pathway, the Ras-MAPK pathway, and the JAK/STAT pathway. The activated IGF1R is involved in cell growth and survival control. Thus, although InsR and IGF1R feed into similar signaling pathways, InsR-mediated signaling predominantly regulates metabolism, whereas IGF1R signaling is involved in cell growth and survival.
An illustrative example of the IGF1R is the human IGF1R with Uniprot Acc. No. P08069 (entry version 185 of Jul. 22, 2015) and variants thereof. IGF1R in the context of the present invention is preferably capable of inducing (i) Akt phosphorylation, and/or (ii) AMPK phosphorylation and/or (iii) mTOR phosphorylation upon binding of their ligand, in particular IGF1.
The term “IGF1” or “IGFI” refers to the Insulin-like growth factor I, a protein structurally and functionally related to insulin, but having a higher growth-promoting activity. An illustrative example is the human IGF1 with Uniprot Acc. No. P05019 (entry version 186 of Jul. 22, 2015). “IGF1” in the context of the present invention is preferably capable of binding to the IGF1 receptor and eliciting IGF1R signaling as described elsewhere herein.
The term “IGF2R” or “IGF2R” or “IGFRII” is used herein to refer to the Insulin-like growth factor 2/mannose-6-phosphate (IGF-2/M6P) receptor. The IGF2R is a single transmembrane protein composed of a large extracytoplasmic (i.e. extracellular) domain, a single transmembrane region and a short cytoplasmic tail that lacks intrinsic catalytic activity. The receptor binds IGF-2 with higher affinity than IGF-1 and does not bind insulin. The IGF2R has been reported to interact, via distinct sites, with lysosomal enzymes and a variety of other M6P-containing ligands, and regulate extracellular IGF-2 concentrations, thereby modulating signaling through the growth-stimulatory IGF-1 receptor pathway.
An illustrative example of the IGF2R is the human IGF2R with Uniprot Acc. No. P11717 (entry version 174 of Jul. 22, 2015) and variants thereof.
The term “IGF2” or “IGFII” refers to the Insulin-like growth factor II. An illustrative example is the human IGF2 with Uniprot Acc. No. P01344 (entry version 199 of Jul. 22, 2015) and variants thereof. “IGF2” in the context of the present invention is preferably capable of binding to the IG2 receptor.
The isolated DNA sequence provided herein may comprise a sequence corresponding to the sequence of IGFR-I2 as shown in SEQ ID No.: 1, or variants thereof as described herein. Variants of the IGFR-I2 gene may also include orthologs. An ortholog, or orthologous gene, is a gene with a sequence that has a portion with similarity to a portion of the sequence of a known gene, but found in a different species than the known gene. An ortholog and the known gene originated by vertical descent from a single gene of a common ancestor.
As used herein a variant or ortholog of the IGFR-I2 gene is envisaged to encode an IGFR-like receptor 2 or a functional variant thereof, i.e. preferably being capable of interacting or binding to IGFR-I1 and having at least about 60%, 65%, 70%, 75%, 80%, 90%, 95%, 97%, 98%, 99%, 99.5% or 100% sequence identity with the IGFR-I2 gene, i.e. sequence identity with the IGFR-I2 gene's coding sequence shown in SEQ ID NO: 1 (cDNA).
As used herein the term “isolated DNA sequence” refers to a DNA molecule purified, or substantially purified, from endogenous material, including other nucleic acid sequences, proteins, peptides, lipids and so on naturally occurring in the cell and/or organism from which the DNA sequence is derived and includes DNA purified by standard purification techniques as well as DNA prepared by recombinant technology and those chemically synthesized.
The nucleic acid of the invention may also be in the form of, may be present in and/or may be part of a vector.
The term “vector” refers a nucleic acid molecule used as a vehicle to transfer (foreign) genetic material into a host cell and encompasses—without limitation—plasmids, viruses, cosmids and artificial chromosomes such as bacterial artificial chromosomes (BACs) and yeast artificial chromosomes (YACs). In general, engineered vectors comprise an origin of replication, a multicloning site and a selectable marker. The vector itself is generally a nucleotide sequence, commonly a DNA sequence that comprises an insert (transgene) and a larger sequence that serves as the “backbone” of the vector. Vectors may encompass additional elements besides the transgene insert and a backbone including gene regulation elements, genetic markers, antibiotic resistances, reporter genes, targeting sequences, or protein purification tags. Particularly envisaged within the context of the invention are expression vectors (expression constructs) for expression of the transgene in the host cell, which generally comprise—in addition to the transgene—gene regulation sequences.
An expression vector is, in general, a vector that can provide for expression of the IGFR-like receptor 2 in vitro and/or in vivo (i.e. in a suitable host cell, host organism and/or expression system). The person skilled in the art will readily understand that choice of a particular vector include depends, e.g., on the host cell, the intended number of copies of the vector, whether transient or stable expression of the IGFR-like receptor 2 is envisaged, and so on.
“Transient expression” results from the introduction of a nucleic acid (e.g. a linear or non-linear DNA or RNA molecule) or vector that is incapable of autonomous replication into a recipient host cell. Expression of the transgene occurs through the transient expression of the introduced sequence.
However, “stable expression” of the nucleic acid sequence as described herein will often be preferred and may be accomplished by either stably integrating the nucleic acid sequence into the host cell's genome or by introducing a vector comprising the nucleic acid sequence of the invention and being capable of autonomously replicating into the host cell.
The vector provided herein is in particular envisaged to comprise a gene regulation element operably linked to the DNA sequence encoding said IGFR-like receptor 2.
The term “gene regulation element” refers to DNA sequences necessary for the expression of an operably linked coding sequence in a particular host organism. The term “gene regulation element” includes controllable transcriptional promoters, operators, enhancers, silencers, transcriptional terminators, 5′ and 3′ untranslated regions which interact with host cellular proteins to carry out transcription and translation and other elements that may control gene expression including initiation and termination codons. The precise nature of the regulatory regions needed for gene expression may vary from organism to organism. Prokaryotic gene regulation elements, for example, include a promoter, optionally an operator sequence, and a ribosome binding site (RBS), whereas gene regulation elements for eukaryotic cells comprise promoters, polyadenylation (poly-A) signals, and enhancers.
The gene regulation element is envisaged to be “operably linked” to the gene to be expressed, i.e. placed in functional relationship with the same. For instance, a promoter or enhancer is “operably linked” to a coding nucleic acid sequence if it affects the transcription of the sequence. The DNA sequences being “operably linked” may or may not be contiguous. Linking is typically accomplished by ligation at convenient restriction sites or synthetic oligonucleotide adaptors or linkers.
Further provided herein is a host cell comprising the vector as described herein.
A variety of host cells can be employed for expressing the nucleic acid sequence encoding the IGFR-like receptor 2 as described herein. Host cells can be prepared using genetic engineering methods known in the art. The process of introducing the vector into a recipient host cell is also termed “transformation” or “transfection” hereinafter. The terms are used interchangeably herein.
Host cell transformation typically involves opening transient pores or “holes” in the cell wall and/or cell membrane to allow the uptake of material. Illustrative examples of transformation protocols involve the use of calcium phosphate, electroporation, cell squeezing, dendrimers, liposomes, cationic polymers such as DEAE-dextran or polyethylenimine, sonoporation, optical transfection, impalefection, nanoparticles (gene gun), magnetofection, particle bombardement, alkali cations (cesium, lithium), enzymatic digestion, agitation with glass beads, viral vectors, or others. The choice of method is generally dependent on the type of cell being transformed, the vector to be introduced into the cell and the conditions under which the transformation is taking place.
As used herein, the term “host cell” refers to any cell or cell culture acting as recipients for the vector or isolated nucleic acid sequence encoding the IGFR-like receptor 2 as described herein. Suitable host cells include prokaryotic or eukaryotic cells, and also include but are not limited to bacteria, yeast cells, fungi cells, plant cells, and animal cells such as insect cells and mammalian cells, e.g., murine, rat, macaque or human.
E.g., the IGFR-like receptor 2 can be produced in bacteria. In addition to prokaryotes, eukaryotic microbes such as filamentous fungi or yeast are suitable cloning or expression hosts for the IGFR-like receptor 2 of the invention. Illustrative examples include Saccharomyces cerevisiae, Schizosaccharomyces pombe, Kluyveromyces hosts such as K. lactis, K. fragilis (ATCC 12424), K. bulgaricus (ATCC 16045), K. wickeramii (ATCC 24178), K. waltii (ATCC 56500), K. drosophilarum (ATCC 36906), K. thermotolerans, and K. marxianus; yarrowia (EP 402 226); Pichia pastoris (EP 183 070); Candida; Trichoderma reesia (EP 244 234); Neurospora crassa; Schwanniomyces such as Schwanniomyces occidentalis; and filamentous fungi such as Neurospora, Penicillium, Tolypocladium, and Aspergillus hosts such as A. nidulans and A. niger.
Suitable host cells for the expression of glycosylated antibody construct of the invention may also be derived from multicellular organisms. Examples of invertebrate cells include plant and insect cells. Numerous baculoviral strains and variants and corresponding permissive insect host cells from hosts such as Spodoptera frugiperda (caterpillar), Aedes aegypti (mosquito), Aedes albopictus (mosquito), Drosophila melanogaster (fruit fly), and Bombyx mori have been identified. A variety of viral strains for transfection are publicly available, e.g., the L-1 variant of Autographa californica NPV and the Bm-5 strain of Bombyx mori NPV.
Plant cell cultures of cotton, corn, potato, soybean, petunia, tomato, Arabidopsis and tobacco can also be used as hosts. Cloning and expression vectors useful in the production of proteins in plant cell culture are known to those of skill in the art.
Examples of useful mammalian host cell lines are monkey kidney CV1 line transformed by SV40 (COS-7, ATCC CRL 1651); human embryonic kidney line (293 or 293 cells subcloned for growth in suspension culture); baby hamster kidney cells (BHK, ATCC CCL 10); Chinese hamster ovary cells/-DHFR (CHO), mouse sertoli cells (TM4); monkey kidney cells (CVI ATCC CCL 70); African green monkey kidney cells (VERO-76, ATCC CRL1587); human cervical carcinoma cells (HELA, ATCC CCL 2); canine kidney cells (MDCK, ATCC CCL 34); buffalo rat liver cells (BRL 3A, ATCC CRL 1442); human lung cells (W138, ATCC CCL 75); human liver cells (Hep G2,1413 8065); mouse mammary tumor (MMT 060562, ATCC CCL5 1); TRI cells; MRC 5 cells; FS4 cells; and human hepatoma cells (Hep G2).
For IGFR-like receptor 1 as previously described, there were binding sites for potential ligands identified that may inter alia serve as a template for providing the diagnostic binding agents and antagonists or agonists of the present invention. Said domains include two insulin-like growth factor binding domains (domain 1: amino acids 273-413 of SEQ ID NO. 4; domain 2: amino acids 579-659 of SEQ ID No. 4), a mannose-6-phosphate receptor binding domain (M6P domain, amino acids 655-857 of SEQ ID No. 4), a transmembrane domain (amino acids 908-930 of SEQ ID NO: 4) and a cytoplasmic domain (amino acids 932-1013 of SEQ ID No: 4). The present invention thus also relates to binding agents, such as e.g. antibodies (monoclonal antibodies being preferred), that specifically bind to at least one of such above mentioned domains as analogously comprised by IGFR-I2.
Accordingly, for IGFR-like receptor 2 binding sites for potential ligands identified include two insulin-like growth factor binding domains (domain 1: amino acids 283-454 of SEQ ID NO. 2; domain 2: amino acids 600-675 of SEQ ID No. 2), a mannose-6-phosphate receptor binding domain (M6P domain, amino acids 669-876 of SEQ ID No. 2), a transmembrane domain (amino acids 930-950 of SEQ ID NO: 2) and a cytoplasmic domain (amino acids 951-1029 of SEQ ID No: 2).
In some embodiments, the disclosure provides a method of generating an antibody against an epitope of the IGFR-like receptor 2, such as from domain 1, domain 2, the M6P domain, the transmembrane domain, or the cytoplasmic domain. The method can involve administering to a mammal an antibody-generating peptide from an IGFR-like receptor 2 domain as set forth in SEQ ID NO: 2; and then purifying the antibody. A peptide corresponding to a sequence in one of the referenced domains and having a length in the range of 10-25 amino acids, or 14-20 amino acids, can be used to immunize a mammal and generate antibodies. An exemplary peptide is (N)-ATKEKEDHFESVQLKTS (see SEQ ID NO: 19)-(C) used to generate antibodies against the cytoplasmic domain of IGFR-like receptor 2.
Proteins comprising an insulin-like growth factor binding domain (InterPro Acc. No. IPR009030) include, without limitation, the insulin-like growth factor-binding proteins (IGFBP1-6), the type-1 insulin-like growth-factor receptor (IGF-1R), the receptor protein-tyrosine kinase Erbb-2, Erbb-3 and Erbb-4 (ErbB2, -3, -4), Ephrin Type A/B receptor, epidermal growth factor receptor (EGFR), EGFR-like binding proteins, CYR61, Matrilin-2, -3 and -4, Delta-like protein 1, Cubilin, Slit homolog 1 and 3 protein, Multiple epidermal growth factor-like domains protein 6, Low-density lipoprotein receptor-related protein 4, WNT1-inducible-signaling pathway protein 2, WNT1-inducible-signaling pathway protein 1, WNT1-inducible-signaling pathway protein 3, EGF-containing fibulin-like extracellular matrix protein 2, Low-density lipoprotein receptor, Pro-epidermal growth factor, Complement component C9, Thrombomodulin, Vitamin K-dependent protein S, Complement component C8 alpha chain, Uromodulin, Furin, Bone morphogenetic protein 1, Nidogen-1, Insulin receptor-related protein, Fibulin-1 and -2, Proprotein convertase subtilisin/kexin type 6, Connective tissue growth factor, Fibrillin-1, -2 and -3, Neurogenic locus notch homolog protein 1, Protein NOV homolog, CD97 antigen, Cartilage oligomeric matrix protein, Keratin, type II cuticular Hb3, Protein jagged-1, Protein crumbs homolog 1, Serine protease HTRA4, Serine protease HTRA3, Low-density lipoprotein receptor-related protein 2, Neurogenic locus notch homolog protein 2, Tumor necrosis factor receptor superfamily member 9, Prolow-density lipoprotein receptor-related protein 1, EGF-containing fibulin-like extracellular matrix protein 1, Nidogen-2, Scavenger receptor class F member 1, Adhesion G protein-coupled receptor E1, Growth arrest-specific protein 6, Keratin, type I cuticular Ha2, Latent-transforming growth factor beta-binding protein 1, Latent-transforming growth factor beta-binding protein 2, R-spondin-1, -2 and -4, Sushi, von Willebrand factor type A, EGF and pentraxin domain-containing protein 1, Uromodulin-like 1, Meckelin, Protein eyes shut homolog, Proprotein convertase subtilisin/kexin type 4, Sushi domain-containing protein 1, Cysteine-rich with EGF-like domain protein 2, Nephronectin, Protocadherin Fat 4, BMP/retinoic acid-inducible neural-specific protein 3, Extracellular matrix protein FRAS1, Epidermal growth factor-like protein 6, Signal peptide, CUB and EGF-like domain-containing protein 1, Signal peptide, CUB and EGF-like domain-containing protein 3, Latent-transforming growth factor beta-binding protein 4, Hemicentin-2, Delta and Notch-like epidermal growth factor-related receptor, Insulin-like growth factor-binding protein-like 1, Serine protease HTRA1, Proprotein convertase subtilisin/kexin type 5, Protein kinase C-binding protein NELL1, von Willebrand factor C and EGF domain-containing protein, Scavenger receptor class F member 2, Cysteine-rich with EGF-like domain protein 1, Kazal-type serine protease inhibitor domain-containing protein 1, Hemicentin-1, Protein kinase C-binding protein NELL2, Neurogenic locus notch homolog protein 4, R-spondin-3, Adhesion G protein-coupled receptor E3, Mucin-13, Endosialin, Cadherin EGF LAG seven-pass G-type receptor 2, Complement component C1q receptor, Endothelial cell-specific molecule 1, Signal peptide, CUB and EGF-like domain-containing protein 2, Delta-like protein 4, Latent-transforming growth factor beta-binding protein 3, Delta-like protein 3, Cadherin EGF LAG seven-pass G-type receptor 1, Low-density lipoprotein receptor-related protein 1B, Cysteine-rich motor neuron 1 protein, Fibulin-5, Epidermal growth factor-like protein 7, Adhesion G protein-coupled receptor E2, Neurogenic locus notch homolog protein 3, Protein jagged-2 and others.
Potential ligands of the IGFR-like receptor 2 described herein thus include ligands of the aforementioned proteins, such as IR, IGF1R, insulin, IGFR-I1, IGF1, IGF2, ephrin-B1, ephrin-B2, EGF, EGFR, TGFA/TGF-alpha, amphiregulin, epigen/EPGN, BTC/betacellulin, epiregulin/EREG, HBEGF/heparin-binding EGF, GP30, ALB, MB, Kappa and lambda-light chains, TF, hemoglobin, GC, SCGB1A1, APOA1, high density lipoprotein, the GIF-cobalamin complex, LRP2, LGALS3, AGRIN, IL-1, IL-2, TNF, collagen I and IV, perlecan, laminin, heparin, integrin, fibronectin, protein C, EFNA5, EFNB1, EFNB2, EFNB3, Jagged1, Jagged2 and Delta1, neuregulins, NTAK, CSPG5, TNFSF9/4-1BBL, Ac-LDL, AXL, TYRO3 MER, NRG1, NRG2, NRG3, NRG4, BTC, EREG, HBEGF, GR4, LGR5, LGR6, C1q, mannose-binding lectin (MBL2), pulmonary surfactant protein A (SPA), TGFBR2, and fragments and variants thereof.
Proteins comprising Mannose-6-phosphate receptor binding domain (InterPro Acc. No. IPR009011) include, without limitation, the cation-independent mannose-6-phosphate receptor, glucosidase 2 subunit β, the cation-dependent mannose-6-phosphate receptor, Protein OS-9, Endoplasmic reticulum lectin 1, and N-acetylglucosamine-1-phosphotransferase subunit gamma.
Potential ligands of the IGFR-like receptor 2 provided herein therefore include ligands of the aforementioned proteins, such as IGF2, DPP4, phosphomannosyl, TRPV4, IGF2, lysosomal enzymes, TGF β, Leukemia inhibitory factor (LIF), Proliferin, Thyroglobulin, Prorenin, Granzyme B, and Retonic Acid.
The present inventors found that knockdown or knockout of the IGFR-like receptor 2 resulted in increased phosphorylation of IGF1R and IR, and of downstream signaling protein Akt. Moreover, it could be observed that reduction of IGFR-like 2 levels leads to modulation of IGFR-like 1, suggesting that IGFR-like 2 regulates internalization, degradation or recycling of IGFR-like 1. It is thus supposed that the IGFR-like receptor 2 may inhibit or dampen IGF1R- and/or IR activation and/or downstream signaling. Without wishing to be bound by specific theory, it is thought that the IGFR-like receptor 2 similar as IGFR-like receptor 1 may for instance function as an “insulin scavenger” receptor depleting insulin from the blood and transferring it to the endo- and lysosomal compartments where it may be degraded. It is also speculated that the IGFR-like receptor 2 after interaction to the previously described IGFR-like receptor 1 may associate with the insulin receptor (InsR), resulting in removal of the InsR from the cell surface. Either way, these scenarios may explain decreased InsR activation and InsR and/or IGF1R-mediated signaling, including phosphorylation of InsR, IGF1R and/or Akt in the presence of functional IGFR-like receptors. Therefore, insulin, InsR and/or the insulin-IR complex are particularly envisaged as ligands for the IGFR-like receptor 2 provided herein.
Further, agonists and antagonists of the IGFR-like receptor 2 described herein are provided. As described herein and demonstrated in the appended examples, the IGFR-like receptor 2 has been found to negatively regulate, i.e. inhibit or reduce InsR- and/or IGF1R-mediated signaling, and in particular Akt phosphorylation (see
The term “antagonist” refers to receptor ligand that inhibits or reduces agonist-mediated biological responses rather than provoking a biological response itself upon binding to the receptor. Antagonists have affinity but essentially no efficacy for their receptors. The term also comprises antagonists binding to the active (orthosteric) or to allosteric sites of their receptors, and/or to other binding sites not normally involved in receptor function. The term “antagonist” in general comprises full and partial antagonists, reversible and irreversible antagonists. In accordance with the invention, the antagonist preferably specifically binds to the IGFR-like receptor 2.
The term “agonist” as used herein generally refers to a receptor ligand that activates the receptor upon binding to produce a biological response. In contrast to antagonists, agonists have both affinity and efficacy for their receptors. The term “agonist” in general comprises full and partial agonists, reversible and irreversible agonists. In accordance with the invention, the agonist preferably specifically binds to the IGFR-like receptor 2.
The “antagonist” or “agonist” of the present invention may in general be any molecule, such as an antibody, a siRNA, a nucleic acid, an aptamer, a peptide, a protein, or a small molecule organic compound, that binds or specifically binds to an IGFR-like receptor 2 as specified herein, or a variant or a fragment thereof, and either blocks or reduces the biological responses mediated by the IGFR-like receptor 2 (i.e. acts as an antagonist) or induces or increases the biological responses mediated by the IGFR-like receptor 2 (i.e. acts as an agonist).
Agonists and antagonists of the IGFR-like receptor 2 can be easily found e.g. using the screening assay as provided herein. The skilled person will readily acknowledge that ligands of proteins comprising e.g. an insulin-like growth factor binding domain and/or a mannose-6-phosphate receptor binding domain (exemplary proteins and ligands have been described in the “Ligands” section above) may be used as a template for preparing agents capable of binding to the IGFR-like receptor 2 and exhibiting an agonistic or antagonistic effect. E.g., in case of protein or peptide ligands, variants and fragments thereof can be easily prepared using routine methods of genetic engineering. The agonists and antagonists of the invention are envisaged to specifically bind to the IGFR-like receptor 2 described herein (i.e. preferably do not exhibit cross-reactivity towards targets other than the IGFR-like receptor 2), as can easily be tested e.g. by evaluating antibody binding in IGFR-like receptor 2 knockdown host cells.
The antagonist or agonist provided herein may be an antibody. The antibodies provided herein preferably exhibit the desired biological activity, i.e. specifically bind to the IGFR-like receptor 2 described herein. It is thus also envisaged that the antibodies of the invention targeting IGFR-like receptor 2 interfere with receptor homo- and heterodimerization of IGFR-I1 and IGFR-I2 and/or ligand binding. Accordingly, an antibody may reduce formation of an IGFR-I1/IGFR-I2 protein complex or formation of an IGFR-I2/IGFR-I2 protein complex.
Also envisaged herein are antibodies which may reduce formation of an IGFR-I1/IGFR-I1 protein complex or formation of an IGFR-I1/InsR or IGFR-I1/IGF-1R complex.
Specifically, it is envisaged that the antagonistic antibodies of the invention are capable of increasing InsR and/or IGF1R-mediated signaling, and in particular phosphorylation of Akt and/or other downstream signaling components that becomes active when either IGFRs or InsR or both transmit a signal, as ascertainable using routine methods known in the art and described in the appended examples. “Increase” thereby denotes an increase in the respective signal in the presence of the antibody when compared to the absence of the antibody in the respective detection method which is used for the detection and/or quantification of said increase. Strikingly, IGFR-I contains an extracellular domain that shows great similarity to the HER2 dimerization region, which is targeted by the antibody trastuzumab (Herceptin®). HER2 is constitutively active being able to dimerize with other HER family members acting in a ligand-independent manner and targeting HER2 by trastuzumab blocks its activity and inhibits cancer growth. Moreover, IGFR-I and IGFR-I2 contain a GxxxG dimerization motif in its transmembrane domain that is found in members of the EGFR family. This suggests that IGFR-I homo- and heterodimerizes with EGFR and IR family members to regulate cell signaling outcome, metabolic vs mitogenic. It is thus also envisaged that the antibodies of the invention targeting IGFR-like receptor 2 interfere with receptor homo- and heterodimerization and/or ligand binding.
Methods to provide such antibodies are well known to the skilled person (e.g. WO/2014/124020) and exemplified hereinafter. One may purify the IGFR-I2 ectodomain (also referred to herein as extracellular domain) as well as the full-length receptor to high purity using a mammalian expression system to generate fully N-glycosylated, properly folded receptor with native conformation. Receptor reconstitution in synthetic membranes not only allows for dimerization of the receptor within a lipid bilayer, but also presents the receptor as an antigen in the membrane context and thus is highly suitable for the generation of the antibodies of the present invention and in particular the therapeutic antibodies of the invention. Thus IGFR-I2 proteoliposomes are a synthetic mimic of the cellular membranes and thus ideal to produce e.g. monoclonal. These antibodies are directed against the extracellular domain of the receptor only and may interfere with receptor homo- and heterodimerization and/or ligand binding. It is thus also envisaged that the antibodies of the invention are capable of binding to the glycosylated IGFR-like receptor 2, preferably to its glycosylated ectodomain.
As is well known in the art, an antibody is an immunoglobulin molecule capable of specific binding to a target (epitope) through at least one epitope recognition site, located in the variable region of the immunoglobulin molecule. The term “antibody” as used herein comprises monoclonal and polyclonal antibodies, as well as (naturally occurring or synthetic) fragments or variants thereof, including fusion proteins comprising an antibody portion with an antigen-binding fragment of the required specificity and any other modified configuration of the antibody that comprises an antigen-binding site or fragment (epitope recognition site) of the required specificity. Illustrative examples include dAb, nanobody, affibody, Fab, Fab′, F(ab′)2, Fv, single chain Fvs (scFv), diabodies, and minibodies comprising a scFv joined to a CH3 domain. It will be understood that other antibody frameworks or scaffolds comprising “antigen-binding sites” can be employed in line with the present invention. The term “antibody” thus also comprises these scaffolds. The mentioned scaffolds include e.g. non-immunoglobulin based antibodies and scaffolds onto which CDRs of the antibodies can be grafted. Such scaffolds include for example anticalins, avimers, affilins etc.
The antibody may be a chimeric antibody (or antigen-binding variant or fragment thereof). The term “chimeric antibody” refers to an antibody in which a portion of the heavy and/or light chain is identical with or homologous to corresponding sequences in antibodies derived from a particular species or belonging to a particular antibody class or subclass, while the remainder of the chain(s) is identical with or homologous to corresponding sequences in antibodies derived from another species or belonging to another antibody class or subclass, as well as fragments of such antibodies.
The antibody may be a humanized antibody (or antigen-binding variant or fragment thereof). The term “humanized antibody” refers to an antibody containing a minimal sequence derived from a non-human antibody. In general, humanized antibodies are human immunoglobulins comprising residues from a hypervariable region of an immunoglobulin derived from non-human species such as mouse, rat, rabbit or non-human primate (“donor antibody”) grafted onto the human immunoglobulin (“recipient antibody”). In some instances, framework region (FR) residues of the human immunoglobulin are replaced by corresponding non-human residues. Furthermore, humanized antibodies may comprise residues that are neither found in the recipient antibody nor in the donor antibody. These modifications are made to further refine antibody performance. In general, the humanized antibody will comprise substantially all of at least one, and typically two, variable domains, in which all or substantially all of the hypervariable loops correspond to those of a non-human immunoglobulin and all or substantially all of the FRs are those of a human immunoglobulin sequence. The humanized antibody optionally also will comprise at least a portion of an immunoglobulin constant region (Fc), typically that of a human immunoglobulin.
The antibody may be a human antibody. A “human antibody” is one that possesses an amino-acid sequence corresponding to that of an antibody produced by a human and/or has been made using any of the techniques for making human antibodies. This definition of a human antibody specifically excludes a humanized antibody comprising non-human antigen-binding residues. Human antibodies can be produced using various techniques known in the art, including phage-display libraries (Hoogenboom and Winter, J. Mol Biol, 227:381 (1991); Marks et al, J. Mol Biol, 222:581 (1991)). Also available for the preparation of human monoclonal antibodies are methods described in Cole et al, Monoclonal Antibodies and Cancer Therapy, Alan R. Liss, p. 77 (1985) and Boerner et al., J. Immunol, 147(I):86-95 (1991). See also van Dijk and van de Winkel, Curr. Opin. Pharmacol, 5:368-374 (2001). Human antibodies can be prepared by administering the antigen to a transgenic animal that has been modified to produce such antibodies in response to antigenic challenge, but whose endogenous loci have been disabled, e.g., immunized xenomice (see, e.g., U.S. Pat. Nos. 6,075,181 and 6,150,584 regarding XENOMOUSE™ technology). See also, for example, Li et al, Proc. Natl. Acad. Sci. USA, 103:3557-3562 (2006) regarding human antibodies generated via a human B-cell hybridoma technology.
The antibodies or antigen-binding variants or fragments thereof used in accordance with of the invention may be modified. Typical modifications conceivable in the context of the invention include, e.g., chemical modifications as described in the following.
Generally, all kind of modifications are conceivable as long as they do not abolish the capability of the antibodies or antigen-binding variants or fragments thereof to specifically bind to the IGFR-like receptor 2 and act as antagonists or agonists of the IGFR-like receptor 2 as described elsewhere herein.
Possible chemical modifications of the antibody or antigen-binding variants or fragments thereof include acylation or acetylation of the amino-terminal end or amidation or esterification of the carboxy-terminal end or, alternatively, on both. The modifications may also affect the amino group in the side chain of lysine or the hydroxyl group of threonine. Other suitable modifications include, e.g., extension of an amino group with polypeptide chains of varying length (e.g., XTEN technology or PASylation®), N-glycosylation, O-glycosylation, and chemical conjugation of carbohydrates, such as hydroxyethyl starch (e.g., HESylation®) or polysialic acid (e.g., PolyXen® technology). Chemical modifications such as alkylation (e. g., methylation, propylation, butylation), arylation, and etherification may be possible and are also envisaged.
As described elsewhere herein, several domains have been identified in the IGFR-like receptor 2 of the invention. Antibodies acting as antagonists or agonists of the IGFR-like receptor 2 are in principle envisaged to bind anywhere in, or in between, the preferably extracellular domains of the IGFR-like receptor 2 as described herein. As such, known antibodies binding to proteins comprising one or more of said domains, are generally also envisaged as antagonists or agonists and can be easily monitored for their antagonistic or agonistic behavior in the screening assay provided herein.
Further, antibodies against the IGFR-like receptor 2 can be prepared as described herein and tested for their agonistic or antagonistic activity as described herein.
The antibodies provided as antagonists or agonists in accordance with the present invention are in particular envisaged to be capable of binding to an IGFR-like receptor 2 epitope within the extracellular domain of IGFR-I2 as shown in SEQ ID NO: 2.
The antibodies preferably bind to the IGFR-like receptor 2 described herein specifically, i.e. not to exhibit cross-reactivity towards non-target molecules such as IGFR-I1, InsR, the IGF1R and IGF2R.
The term “epitope” in general refers to a site on an antigen to which a binding domain, such as an antibody or immunoglobulin or derivative or fragment of an antibody or of an immunoglobulin, specifically binds. An “epitope” is antigenic and thus the term epitope is sometimes also referred to herein as “antigenic structure” or “antigenic determinant”. Thus, the binding domain is an “antigen interaction site”. Said binding/interaction is also understood to define a “specific recognition”. The term “epitope” encompasses linear epitopes and conformational epitopes. Linear epitopes are contiguous epitopes comprised in the amino acid primary sequence and typically include at least 3 or at least 4, and more usually, at least 5 or at least 6 or at least 7, for example, about 8 to about 10 amino acids in a unique sequence. Conformational epitopes are formed by non-contiguous amino acids juxtaposed by folding of the protein. Methods of determining the conformation of epitopes include, but are not limited to, x-ray crystallography, two-dimensional nuclear magnetic resonance (2D-NMR) spectroscopy and site-directed spin labelling and electron paramagnetic resonance (EPR) spectroscopy.
Other molecules are also envisaged herein as antagonists or agonists of the IGFR-like receptor 2.
siRNAs and nucleic acids are particularly useful as IGFR-like receptor 2 antagonists that reduce or inhibit expression of IGFR-I2 gene as shown in SEQ ID NO: 1 (or variants or orthologs thereof). The term “siRNA” is used interchangeably with “small interfering RNA” or “silencing RNA”. siRNAs are double-stranded “antisense” RNA molecules, typically including a sequence of at least 20 consecutive nucleotides having at least 95% sequence identity to the complement of the sequence of the target nucleic acid, such as the coding sequence of the IGFR-I2 gene, but may as well be directed to regulatory sequences of said gene, including the promoter sequences and transcription termination and polyadenylation signals.
Other nucleic acids capable of reducing and/or inhibiting IGFR-like receptor 2 expression include aptamers, Spiegelmers®, nc-RNAs (including anti-sense-RNAs, L-RNA Spiegelmer, silencer RNAs, micro-RNAs (miRNAs), short hairpin RNAs (shRNAs), small interfering RNAs (siRNAs), repeat-associated small interfering RNA (rasiRNA), and molecules or an RNAs that interact with Piwi proteins (piRNA). Such non-coding nucleic acid molecules can for instance be employed to direct IGFR-like receptor 2 mRNA degradation or disrupt IGFR-like receptor 2 mRNA translation. A respective reactant, in particular siRNA molecule, may in principle be directly synthesized within the host cell, or may be introduced into the host cell.
Peptides and proteins can in general be employed as IGFR-receptor 2 antagonists or agonists, depending on whether they increase (antagonists) or decrease (agonists) the biological responses mediated by IGFR-like receptor 2 signaling. The term “polypeptide” and “protein” are used interchangeably herein. It is envisaged that proteins and peptides bind specifically to the IGFR-like receptor 2. As set out previously herein, the skilled person will readily be able to find peptide and protein antagonists or agonists capable of specifically binding to the IGFR-like receptor 2. Small organic molecules are, too, capable of either acting as IGFR-like receptor 2 antagonists or agonists. It is envisaged that small organic molecules specifically bind to the IGFR-like receptor 2. High-throughput screening assays for small organic molecules are readily available in the art and can be employed to find ligands of the IGFR-like receptor 2 provided herein that may exhibit agonistic or antagonistic activity.
As set out herein, specific binding of the binding agents, in particular antagonists and agonists provided herein, e.g. antibodies, to the IGFR-like receptor 2 is preferred. The terms “binding to” and “recognizing” in all grammatical forms are used interchangeably herein.
The term “specifically binds” generally indicates that a binding agent, in particular an antagonist or agonist, such as an antibody, binds with higher affinity to its intended target (i.e. the IGFR-like receptor 2 described herein) than to its non-target molecule. Non-target molecules include the IGF receptors, in particular IGFR-I1, the human IGF1R with Uniprot Acc. No. P08069 (entry version 185 of 22 Jul. 2015), the human IGF2R with Uniprot Acc. No. P11717 (entry version 174 of 22 Jul. 2015), and the human InsR with Uniprot Acc. No. P06213 (entry version 216 of 22 Jul. 2015); and functional variants thereof. Preferably the affinity of the agonist or antagonist will be at least about 5 fold, preferably 10 fold, more preferably 25-fold, even more preferably 50-fold, and most preferably 100-fold or more, greater for a target molecule than its affinity for a non-target molecule. Preferred antibodies bind with affinities of at least about 107 M−1, and preferably between about 108 M−1 to about 109 M−1, about 109 M−1 to about 1010 M−1, or about 1010 M−1 to about 1012 M−1.
Preferably, the term “specifically binds” thus indicates that an antagonist or agonist, such as an antibody, exclusively binds to its intended target (i.e., the IGFR-like receptor 2).
It is envisaged that the IGFR-like receptor 2 antagonists and agonists are particularly useful in treatment and diagnostic of cancer and diabetes. As used herein, “cancer” refers to all disorders associated with uncontrolled cell proliferation in any tissue, and particularly comprises endometrial cancer, gastric cancer, breast cancer, prostate cancer, lung cancer, and/or brain cancer (in particular pituitary gland cancer). The term “diabetes” as used herein refers to the broad class of disorders characterized by impaired insulin production and glucose tolerance and in general includes type 1 and type 2 diabetes (also called juvenile and adult-onset, respectively), gestational diabetes, prediabetes, insulin resistance, metabolic syndrome, and impaired glucose tolerance. Diabetes results from a deficiency or functional impairment of insulin-producing β cells, alone or in combination with insulin resistance.
The term “metabolic syndrome” comprises abdominal (central) obesity, elevated blood pressure, elevated fasting plasma glucose, high serum triglycerides, low high-density lipoprotein (HDL) and/or high low-density lipoprotein (LDL) levels. Further it is associated with the risk of developing type 2 diabetes and/or cardiovascular disease including coronary heart diseases.
The term “β cell(s)”, “beta cell(s)” and “islet cell(s)” are used interchangeably herein to refer to the pancreatic β cells located in the islet of Langerhans. Their primary function is to store and release insulin.
Defective insulin secretion underlies all forms of diabetes mellitus. Whereas the destruction of β-cells is responsible for type 1 diabetes (T1D), both lowered β-cell mass and loss of secretory function are implicated in type 2 diabetes (T2D). Emerging results suggest that a functional deficiency, involving de-differentiation of the mature β-cell towards a more progenitor-like state, may be an important driver for impaired secretion in T2D.
It is contemplated that the antagonists and agonists of the present invention can advantageously be employed in preventing β cell de-differentiation and/or reverting β cell loss-of-function. The antagonist and agonists described herein are therefore envisaged for use as a medicament. Particularly, said antagonists and agonists are intended for use in a method of prophylactic and/or therapeutic treatment of diabetes. Further, the use of said antagonists and agonists for the manufacture of a medicament for therapeutic application in diabetes or cancer is also contemplated by the present invention.
Type 1 diabetes is also known as Insulin Dependent Diabetes Mellitus (IDDM), and juvenile diabetes. The terms are used interchangeably herein. This form accounts for 5-10% of diabetes and is thought to be due to cellular-mediated autoimmune destruction of the pancreatic β-cells, resulting in little or no insulin secretion. Antagonists and agonists of the IGFR-like receptor 2 provided herein may be capable of preventing or even reverting β cell de-differentiation and/or loss-of-function. Thus, the present invention is envisaged to open up new possibilities for a preventive or regenerative therapy of T1D.
Type 2 diabetes is also referred to as adult-onset diabetes and accounts for ˜90-95% of all diabetes. Insulin resistance in target tissues and a relative deficiency of insulin secretion from pancreatic β-cells are the major features of type 2 diabetes (T2D). Insulin resistance is used herein to denote a condition characterized by the failure of target cells to respond to insulin, leading to hyperglycemia. Pancreatic β cells in the pancreas subsequently increase their production of insulin, leading to hyperinsulinemia.
As further shown in the appended examples, the present inventors demonstrated that the IGFR-like receptor 2 described herein negatively regulates insulin downstream signaling. IGFR-like receptor 2 antagonists are therefore envisaged to promote or restore InsR downstream signaling, whereas IGFR-like receptor 2 agonists are thought to inhibit or dampen InsR signaling. IGFR-like receptor 2 antagonists are therefore preferably capable of increasing InsR and/or IGF1R-mediated Akt phosphorylation and/or increasing InsR and/or IGF1R-mediated phosphorylation of other downstream signaling components that become active when either IGFRs or InsR or both transmit a signal, thereby advantageously increasing insulin sensitivity in insulin-resistant cells.
The present invention further provides a binding molecule capable of specifically binding to an IGFR-like receptor 2 as described herein for use as a diagnostic marker for diabetes or the risk of developing diabetes. Preferably, said IGFR-like receptor 2 comprises a sequence corresponding to sequence SEQ ID No 2, however, variants of said IGFR-like receptor 2 are also envisaged.
In general, in order to provide a diagnostic binding agent, the skilled person may follow the same principles as set out in the context of providing antagonists and agonists of the IGFR-like receptor 2. Likewise, diagnostic binding agents provided herein are envisaged to specifically bind to the IGFR-like receptor 2 provided herein. Diagnostic binding agents may exhibit antagonistic or agonistic activities (thereby e.g. enabling simultaneous diagnosis and (preventive) treatment, or may not have an effect on IGFR-like receptor 2 signaling at all.
Particularly useful binding agents for use within the in vitro diagnostic binding assay comprise monoclonal antibodies, e.g. antibodies specifically recognizing an IGFR-like receptor 2 epitope, preferably within its extracellular domain.
The diagnostic binding agents employed in the methods of the invention may further comprise a detectable label attached to the diagnostic binding agent. The detectable label may be (preferably covalently) attached to the diagnostic binding agents either directly or via spacers of various lengths to reduce potential steric hindrance. Various methods for labelling proteins are known in the art and can be used in performing the present invention. The term “label” or “labelling group” refers to any detectable label. Suitable labels for use in with the diagnostic binding agent include, without limitation, (i) isotopic labels, which may be radioactive or heavy isotopes, such as radioisotopes or radionuclides (e.g., 3H, 14C, 15N, 35S, 89Zr, 90Y, 99Tc, 111In, 125I, 131I), (ii) magnetic labels (e.g., magnetic particles), (iii) redox active moieties, (iv) optical dyes (including, but not limited to, chromophores, phosphors and fluorophores) such as fluorescent labels (e.g., FITC, rhodamine, lanthanide phosphors), chemiluminescent labels, and fluorophores which can be either “small molecule” fluorophores or proteinaceous fluorophores, (v) enzymatic groups (e.g. horseradish peroxidase, β galactosidase, luciferase, alkaline phosphatase), (vi) biotinylated groups, (vii) predetermined polypeptide epitopes recognized by a secondary reporter (e.g., leucine zipper pair sequences, binding sites for secondary antibodies, metal binding domains, epitope tags, etc.).
By “fluorescent label” is meant any molecule that may be detected via its inherent fluorescent properties. Suitable fluorescent labels include, but are not limited to, fluorescein, rhodamine, tetramethylrhodamine, eosin, erythrosin, coumarin, methyl-coumarins, pyrene, Malacite green, stilbene, Lucifer Yellow, Cascade BlueJ, Texas Red, IAEDANS, EDANS, BODIPY FL, LC Red 640, Cy 5, Cy 5.5, LC Red 705, Oregon green, the Alexa-Fluor dyes (Alexa Fluor 350, Alexa Fluor 430, Alexa Fluor 488, Alexa Fluor 546, Alexa Fluor 568, Alexa Fluor 594, Alexa Fluor 633, Alexa Fluor 660, Alexa Fluor 680), Cascade Blue, Cascade Yellow and R-phycoerythrin (PE) (Molecular Probes, Eugene, OR), FITC, Rhodamine, and Texas Red (Pierce, Rockford, IL), Cy5, Cy5.5, Cy7 (Amersham Life Science, Pittsburgh, PA). Suitable optical dyes, including fluorophores, are described in Molecular Probes Handbook by Richard P. Haugland. Exemplary proteinaceous fluorescent labels also include, but are not limited to, green fluorescent protein, including a Renilla, Ptilosarcus, or Aequorea species of GFP, EGFP, blue fluorescent protein (BFP), enhanced yellow fluorescent protein (EYFP), luciferase, and β galactosidase.
It is within the knowledge of the skilled person to choose a suitable label depending on the type of diagnostic binding agent, its chemical properties and intended detection method. Particularly suitable diagnostic binding agents for use in the methods of the invention are monoclonal antibodies, preferably specifically recognizing the IGFR-like receptor 2 described herein.
The term “patient” or “subject” as used herein refers to a human or non-human animal, generally a mammal. Particularly envisaged is a mammal, such as a rabbit, a mouse, a rat, a Guinea pig, a hamster, a dog, a cat, a pig, a cow, a goat, a sheep, a horse, a monkey, an ape or preferably a human. Thus, the methods, uses and compounds described in this document are in general applicable to both human and veterinary disease.
The term “treatment” in all its grammatical forms includes therapeutic or prophylactic treatment. A “therapeutic or prophylactic treatment” comprises prophylactic treatments aimed at the complete prevention of clinical and/or pathological manifestations or therapeutic treatment aimed at amelioration or remission of clinical and/or pathological manifestations of the diseases. The term “treatment” thus also includes the amelioration or prevention of diabetes.
In the context with the present invention the term “therapeutic effect” in general refers to the desirable or beneficial impact of a treatment, e.g. amelioration or remission of the disease manifestations. The term “manifestation” of a disease is used herein to describe its perceptible expression, and includes both clinical manifestations, hereinafter defined as indications of the disease that may be detected during a physical examination and/or that are perceptible by the patient (i.e., symptoms), and pathological manifestations, meaning expressions of the disease on the cellular and molecular level. The therapeutic effect of treatment with the IGFR-I2 antagonists and agonists can be assessed using routine methods in the art, e.g. measuring insulin levels and/or glucose levels in blood samples of the patient. Additionally or alternatively it is also possible to evaluate the general appearance of the respective patient (e.g., fitness, well-being) which will also aid the skilled practitioner to evaluate whether a therapeutic effect has been elicited. The skilled person is aware of numerous other ways which are suitable to observe a therapeutic effect of the compounds of the present invention.
Preferably, a therapeutically effective amount of the compound as described herein is administered. By “therapeutically effective amount” is meant an amount of the compound as described herein that elicits a therapeutic effect. The exact dose of IGFR-like receptor 2 antagonists or agonists will depend on the purpose of the treatment (e.g. remission maintenance vs. treatment of acute flare of the disease), and will be ascertainable by one skilled in the art using known techniques. Adjustments for route of administration, age, body weight, general health, sex, diet, time of administration, drug interaction and the severity of the condition may be necessary, and will be ascertainable with routine experimentation by those skilled in the art.
A variety of routes are applicable for administration of the compound according to the present invention, including, but not limited to, orally, topically, transdermally, subcutaneously, intravenously, intraperitoneally, intramuscularly or intraocularly. However, any other route may readily be chosen by the person skilled in the art if desired.
It is envisaged to administer the IGFR-I2 antagonists or agonists in the form of a pharmaceutical composition. Preferably, said antagonists or agonists are present in the pharmaceutical composition in a therapeutically effective amount. Particularly preferred antagonists or agonists for use in the pharmaceutical composition provided herein are monoclonal antibodies specifically binding to the IGFR-like receptor 2 described herein.
The term “pharmaceutical composition” particularly refers to a composition suitable for administering to a human, i.e., a composition that is preferably sterile and/or contains components which are pharmaceutically acceptable. However, compositions suitable for administration to non-human animals are also envisaged herein. Preferably, a pharmaceutical composition comprises an IGFR-I2 antagonist or agonist together with one or more pharmaceutical excipients. The term “excipient” includes fillers, binders, disintegrants, coatings, sorbents, antiadherents, glidants, preservatives, antioxidants, flavoring, coloring, sweeting agents, solvents, co-solvents, buffering agents, chelating agents, viscosity imparting agents, surface active agents, diluents, humectants, carriers, diluents, preservatives, emulsifiers, stabilizers or tonicity modifiers. Pharmaceutical compositions of the invention can be formulated in various forms, e.g. in solid, liquid, gaseous or lyophilized form and may be, inter alia, in the form of an ointment, a cream, transdermal patches, a gel, powder, a tablet, solution, an aerosol, granules, pills, suspensions, emulsions, capsules, syrups, liquids, elixirs, extracts, tincture or fluid extracts or in a form which is particularly suitable for the desired method of administration.
The pharmaceutical composition of the present invention may further comprise one or more additional agents. Preferably, said agents are therapeutically effective for treatment the diseases described herein and present in the composition in a therapeutically effective amount.
In view of the above, the present invention hence also provides a pharmaceutical composition comprising an IGFR-I2 antagonist or agonist. Said pharmaceutical composition is particularly intended for use in a method of therapeutic and/or prophylactic treatment of diabetes or cancer.
A kit is also provided herein. The kit may be a kit of two or more parts, and comprises the IGFR-like receptor 2 antagonist or agonist, preferably in a therapeutically effective amount and in a pharmaceutically acceptable form. The components of the kit may be contained in a container or vials. The kit is envisaged to comprise additional agents useful in treating diabetes or cancer, as described elsewhere herein.
The IGFR-I2 antagonist or agonist and the additional agents can be administered simultaneously or sequentially to the patient.
When used herein the term “screening assay” is equivalently used with the term “screening method”. Such assay or method is preferably performed “in vitro”. However, it can also be performed “in vivo”.
Antagonists and agonists of the IGFR-like receptor 2 can be identified using an in vitro screening assay as provided herein, said assay comprises the following steps: (a) providing a stable cell line expressing said IGFR-like receptor 2; (b) contacting said cell line of (a) with a candidate antagonist or agonist; and (c) measuring an IGFR-like receptor 2 downstream signaling event, wherein an antagonist is identified by increasing said IGFR-like receptor 2 downstream signaling event, and an agonist is identified by decreasing said IGFR-like receptor 2 downstream signaling event; wherein said IGFR-like receptor 2 comprises a sequence corresponding to sequence SEQ ID No. 2.
Optionally, in the herein described screening methods, a cell line, preferably the same cell line as is applied in the screening methods of the present invention, expressing said IGFR-like receptor 2 is not contacted with a candidate antagonist or agonist, respectively. Such cell line serves as control. In such a control cell line also an IGFR-like receptor 2 downstream signaling event is measured and compared to the IGFR-like receptor 2 downstream signaling event measured in a cell line that is (or was) contacted with a candidate antagonist or agonist.
IGFR-like receptor 2 expression is preferably in the pancreas, in pancreatic β-cells. Expression may also be detected in the pituitary gland (e.g. hormone-producing cells). This may implicate an important role of IGFR-like receptor 2 in the regulation of the hypothalamic-pituitary-gonadal (HPG) axis, which controls growth and metabolism. Further, expression may also be detected in breast cancer (e.g. MCF7 cell line).
Additionally, both receptors, IGFR-like receptor 1 and 2 may be expressed simultaneously in cells, such as in pancreatic β-cells.
Preferred examples of cell lines expressing said IGFR-like receptor 2 comprise Min6 or PDX1+/NKX6.1+ iPSC.
As described herein, IGFR-like receptor 2 downstream signaling events are thought to result in a negative regulation of InsR- and/or IGF1R-mediated signaling, and in particular in inhibited or reduced Akt phosphorylation, and/or inhibited or reduced phosphorylation of other downstream signaling components that become active when either IGFRs or InsR or both transmit a signal. As such, a binding agent promoting or increasing Akt phosphorylation, and/or phosphorylation of other downstream signaling components that become active when either IGFRs or InsR or both transmit a signal, in the screening assay provided herein is likely an antagonist of the IGFR-like receptor 2. A binding agent not having any effect on or even reducing Akt phosphorylation, and/or on reducing phosphorylation of other downstream signaling components that become active when either IGFRs or InsR or both transmit a signal, in the screening assay provided herein is likely an agonist of the IGFR-like receptor.
The stable cell line may be any cell line suitable for expressing a functional IGFR-like receptor 2, wherein a “functional IGFR-like receptor 2” is particularly envisaged to bind or interact with IGFR-I1 as described herein elsewhere.
The invention also relates to an antagonist or agonist obtainable by the screening method.
The present invention also contemplates a method for detecting whether IGFR-like receptor 2 homo-or heterodimerizes with IGFR-I1, IGFR-1, IGFR-2 and/or InsR. Said method comprises detecting whether a tagged IGFR-like receptor 2 homodimerizes or heterodimerizes. Heterodimers may include the IGFR-I2 with IGFR-I1, or IGFR-I2 with any of InsR, IGFR-1 and/or IGF-R2.
Preferred tags are fluorescent proteins, such as GFP or Venus, a genetic mutant of green fluorescent protein (GFP) with an emission peak of 527 nm.
Tagging the IGFR-like receptor 2 is preferably achieved by fusing a tag in frame to said IGFR-like receptor 2. This may be achieved by techniques known in the art, e.g. by knocking-in the nucleotide sequence encoding said IGFR-like receptor 2 a nucleotide sequence encoding a tag, e.g. by genome editing, such as using the CRISPR/Cas system.
It is noted that as used herein, the singular forms “a”, “an”, and “the”, include plural references unless the context clearly indicates otherwise. Thus, for example, reference to “a reagent” includes one or more of such different reagents and reference to “the method” includes reference to equivalent steps and methods known to those of ordinary skill in the art that could be modified or substituted for the methods described herein.
Unless otherwise indicated, the term “at least” preceding a series of elements is to be understood to refer to every element in the series. Those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, many equivalents to the specific embodiments of the invention described herein. Such equivalents are intended to be encompassed by the present invention.
The term “and/or” wherever used herein includes the meaning of “and”, “or” and “all or any other combination of the elements connected by said term”.
The term “about” or “approximately” as used herein means within 20%, preferably within 10%, and more preferably within 5% of a given value or range. It includes, however, also the concrete number, e.g., “about 20” includes 20.
The term “less than” or “greater than” includes the concrete number. For example, less than 20 means less than or equal to. Similarly, more than or greater than means more than or equal to, or greater than or equal to, respectively.
Throughout this specification and the claims which follow, unless the context requires otherwise, the word “comprise”, and variations such as “comprises” and “comprising”, will be understood to imply the inclusion of a stated integer or step or group of integers or steps but not the exclusion of any other integer or step or group of integer or step. When used herein the term “comprising” can be substituted with the term “containing” or “including” or sometimes when used herein with the term “having”.
When used herein “consisting of” excludes any element, step, or ingredient not specified in the claim element. When used herein, “consisting essentially of” does not exclude materials or steps that do not materially affect the basic and novel characteristics of the claim.
It should be understood that this invention is not limited to the particular methodology, protocols, material, reagents, and substances, etc., described herein and as such can vary. The terminology used herein is for the purpose of describing particular embodiments only, and is not intended to limit the scope of the present invention, which is defined solely by the claims.
All publications and patents cited throughout the text of this specification (including all patents, patent applications, scientific publications, manufacturer's specifications, instructions, etc.), whether supra or infra, are hereby incorporated by reference in their entirety. Nothing herein is to be construed as an admission that the invention is not entitled to antedate such disclosure by virtue of prior invention. To the extent the material incorporated by reference contradicts or is inconsistent with this specification, the specification will supersede any such material.
A better understanding of the present invention and of its advantages will be had from the following examples, offered for illustrative purposes only. The examples are not intended to limit the scope of the present invention in any way.
All mice were housed in the central facilities at HMGU in accordance with the German animal welfare legislation and acknowledged guidelines of the Society of Laboratory Animals (GV-SOLAS) and of the Federation of Laboratory Animal Science Associations (FELASA). Sacrifice of mice at embryonic stages was not subject to regulatory authorization.
Targeted ES cell clones derived from C57BL/6N parental cell line JM8.N4 were obtained from the EUCOMM cell repository (EuMMCR) (Helmholtz Zentrum Muenchen GmbH, Alleles produced for the EUCOMM and EUCOMMTools projects by the Helmholtz Zentrum Muenchen GmbH (Hmgu). MGI Direct Data Submission. 2010-2015) and were injected into CD1 blastocysts for chimera generation. The resulting chimeras were mated to CD1 or C57BL/6J mice, and the progeny were screened by PCR to confirm germline transmission. Heterozygous mice carrying the targeted mutation were intercrossed to generate homozygous mutant mice either in CD1 or C57BL/6J background.
Genotyping was confirmed by PCR using genomic DNA extracted from the tails of control and knockout mice.
To assess cell proliferation in mutant embryos the pregnant females were injected subcutaneously with 0.1 mg EdU/gram body weight. After two hours, the animals were sacrificed and pancreata from E14.5, E16.5 and E18.5 embryos were dissected and fixed in 4% PFA in PBS pH 7.4 overnight at 4° C. Next day the organs were subjected to a 7.5%, 15%, 30% sucrose gradient embedded in Tissue Freezing Medium (Leica, Germany) and stored at −80° C. 20 micrometer cryosections were stained using Click-iT® EdU Imaging Kit (Life Technology) according to the manufacturer's instructions including antibodies against Insulin (1:250 guinea pig Thermo Scientific; PA1-26938). Images were acquired using a Leica SP5 Confocal microscope with a 20× objective and data analysis was performed using IMARIS software (Bitplane, Switzerland).
For gene expression analysis, by real time quantitative PCR, mRNA was isolated from pancreata of knockout and control embryos using miRNeasy mini kit (Qiagen, Germany). The cDNA was synthesized using GoScript™ Reverse Transcription System (Promega) and subsequently used for qPCR using TaqMan® Low Density Arrays and run on a ViiA 7 system (Applied Biosystems). The probes used are listed in table 4:
Generation of Monoclonal Antibody against Estrogen-induced gene 121 protein (EIG).
Peptides from human EIG protein were synthesized and coupled to OVA (Peps4LS, Heidelberg, Germany). Lou/c rats or C57BL/6 mice were immunized subcutaneously and intraperitoneally with a mixture of 50 μg peptide-OVA, 5 nmol CPG oligonucleotide (Tib Molbiol, Berlin), 500 μl (mouse 100 μl) PBS and 500 μl (mouse 100 μl) incomplete Freund's adjuvant. A boost without adjuvant was given six weeks after the primary injection. Fusion was performed using standard procedures. Supernatants were tested in a differential ELISA with the biotinylated EIG peptides and an irrelevant biotinylated peptide on avidin coated ELISA plates. MAbs that reacted specifically with the EIG peptide were further analysed in Western blot. The peptide (17-mer) (N)-ATKEKEDHFESVQLKTS (see SEQ ID NO: 19)-(C), which is 1008-1024 of hEIG (IGFR-like receptor 2; SEQ ID NO: 2) was used to generate mAb28G11.
Min6 is a pancreatic β-cell line which is well characterized for their ability to secret insulin upon glucose stimulation. This cell line was from Susumu Seino's Lab.
Min6 cells were maintained in high glucose Dulbecco's modified Eagle medium of Gibco (41966-052) supplemented with 10% fetal bovine serum (FBS), 1% Penicillin/Streptomycin and 2-mercaptoethanol.
Min6 cells were seeded at a cell density of 5×104 cells/cm2 and cultured in high glucose DMEM medium. After one transfection of IGFR-like receptor siRNA at day two and day three, cells were lysed in RIPA buffer on ice at day 4 at a cell density of 50-60%. The lipofectamin (Lipofectamine 2000, Life Technologies, #11668019) based transfection was performed according to the protocol of Life Technologies and 200 pmol of following siRNA from Dharmacon GE Healthcare were used: On-Target plus mouse 5330417C22Rik (229722) siRNA-SMARTpool L-048745-01-0020 and control siRNA On-target plus non-targeting siRNA #1 D-001810-01-20.
CRISPR/Cas9-mediated single IGFR-I knock-out (SKO) and double KO strategy in Min6 cells that targets transcriptional start codons (ATG).
Min6 cells were seeded at a cell density of 5×104 cells/cm2 and cultured in high glucose DMEM medium. After performing a IGFR-like receptor knock-down Min6 cells were washed six times with 1×PBS and HBSS buffer containing 0.2% BSA was added for 15 min, 30 min, 60 min and 120 min to starve the cells. Subsequently, cells were lysed in RIPA buffer on ice.
Cells and tissues were lysed in RIPA buffer (50 mM Tris pH 7.5, 150 mM NaCl, 1 mM EDTA, 1% IGEPAL, 0.1% SDS, 0.1% Na deoxycholate) containing a cocktail of proteinase inhibitor (1:100, Sigma, P8340) and phosphatases inhibitors (1:100, Sigma Aldrich, #2 P0044 and #3 P5726) and the cell or tissue lysates were cleared by centrifugation at 13000 r.p.m. for 10-30 min. The proteins (10-20 μg) were resolved in 6.5-15% SDS-PAGE according to the protein size to be detected and transferred to a PVDF membrane. Primary antibodies were added to the membrane in 5% milk and incubated at 4° C. overnight. Protein bands were visualized on Hyperfilms (GE healthcare, 28906837) or Blaufilme CEA-RP (Ernst Christiansen GmbH, EC84A) by chemiluminescent detection (ECL, Millipore, WBKLS0500).
The following antibodies were used with corresponding dilutions:
IGFR-like receptor SEQ ID No. 2 (1:5000 rabbit Pineda, Berlin, Germany), IGFR-like receptor SEQ ID No. 2 (1:100 rat and mouse), IGFR-like receptor SEQ ID No. 4 and 6 (1:10 rat and mouse), Akt (1:5000 Cell Signaling, 4691), P-Akt (1:5000 Cell Signaling, 4060), Erk (1:5000 Cell Signaling, 4695), P-Erk (1:5000 Cell Signaling, 4370), m-Tor (1:1000 Cell Signaling, 2972), P-mTor (1:1000 Cell Signaling, 5536), Ampk (1:1000 Cell Signaling, 2532), P-Ampk (1:2500 Cell Signaling, 2535), IRS-2 (1:1000 Cell Signaling, 4502), IRβ (1:1000 Cell Signaling, 3025), S6rp (1:5000 Cell Signaling, 2217S), P-S6RP (1:5000 Cell Signaling, 2211S), P-IR/IGFR (1:1000, Millipore, 07-841), α-Tubulin (1:5000, Sigma, T7451), mouse Adaptin beta clone 74 (1:5000, BD Bioscience 610382). For the detection of autophagy related proteins the Autophagy Antibody Sampler Kit (#4445, 1:1000) of Cell Signaling was used.
For immunocytochemistry, Min6 cells were plated in Ibidi (Munich, Germany) 8-well chamber dishes (treated) at a cell density of 5×104 cells/well. Three days after seeding cells were directly fixed with 4% PFA for 10 min followed by a 10 min incubation in permeabilization solution (0.1 M Glycin, 0.2% Triton-X100 in 1× PBS). After blocking (10% donkey serum, 1% BSA and 5% FCS, 0.5% Tween-20 in 1×PBS) for 1 h, cells were incubated in blocking solution containing primary antibodies overnight at 4° C.: IGFR-like receptor Seq ID No. 2 (rat and mouse 1:10), GM130 (1:300, BD, 610822), IGF2R (1:100 ThermoScientific, PA3-850). The following secondary antibodies were applied for 2 h at room temperature in blocking solution: donkey anti-rabbit IgG-555 (1:800, Invitrogen, A31572), donkey anti-mouse IgG-488 (1:800, Invitrogen, A21202), and donkey anti-rat IgG 647 (1:400, Dianova, 712-605-150). After DAPI staining (50 ng/ml), the samples were mounted with elvanol and images were acquired on a Leica laser-scanning SP5 confocal microscope with 63× objective.
For immunohistochemistry in mouse tissue, pancreata were dissected and fixed in 4% PFA in PBS for 2 h at 4° C., cryoprotected in a gradient series of sucrose solutions (7.5, 15 and 30% sucrose in PBS) for at least 2 h in each solution and finally the organs were embedded in Tissue Freezing medium (Leica 14020108926) and stored at −80° C. 20 μm sections were used for immunostaining. Briefly the sections were washed in PBS, permeabilized in 0.1% Triton X-100, 0.1M Glycine in PBS for 15 minutes and then blocked in blocking solution (10% FCS, 3% Donkey serum, 0.1% BSA and 0.1% Tween-20 in PBS) for 1 h at room temperature. Primary antibodies were diluted in blocking solution and incubated over night at 4° C. Next day the sections were washed three times for 5 minutes each in PBST (0.1% Tween-20 in PBS) incubated in secondary antibodies diluted in blocking solution for 3-5 h at room temperature, stained with DAPI (4′,6-diamidin-2-phenylindol) and mounted in embedding medium (ProLong Gold antifade embedding medium, Life Technologies).
For whole-mount staining of the human islets, the islets were fixed in 4% PFA in PBS for 15 min at RT and directly incubated overnight at 4° C. with primary antibodies diluted in blocking solution followed by three washes in PBST and then incubated with secondary antibodies for 3-5 hours at RT as above.
For staining of human tissue sections snap frozen pancreata pieces from human donors were embedded in Tissue Freezing medium (Leica 14020108926) and stored at −80° C. 10 μm thick section sections were fixed in in 4% PFA in PBS for 20 min at RT, washed 2 times with PBS and permeabilized for 5 min on ice. Antibodies staining procedure was performed as described above.
Primary antibodies used were anti-IGFR-like receptor rabbit SEQ ID No 2 1:100, anti-IGFR-like receptor SEQ ID No:2 and SEQ ID No. 4 rat 1:10, IGFR-like receptor SEQ ID No 2 and SEQ ID No. 6 mouse 1:10, anti-Insulin (Rabbit 1:250; Cell Signaling; 3014), anti-Insulin (Guinea pig 1:250; Thermo Scientific; PA1-26938), anti-E-Cadherin (Rat 1:500; DECMA Kremmer;) anti-Mannose 6P receptor (Rabbit 1:200; Thermo Scientific; PA3-850) and anti-Urocortin 3 (Rabbit 1:300; Phoenix Pharmaceuticals; H-019-29). Secondary antibodies used were Anti-Rabbit Alexa-555 (1:800; Invitrogen; A31572), Anti-Rabbit Alexa-488 (1:800; Invitrogen; A21206), Anti-Rat Alexa-488 (1:800; life technologies, A-21208), Anti-Rat Alexa-647 (1:800; Dianova, 712-605-150) and Anti-Guinea Pig Alexa647 (1:800; Dianova; 706-495-148) Anti-mouse Alexa-555 (1:800; Invitrogen; A31570). Pictures were taken on a Leica DMI 6000 microscope.
For immunoprecipitation assay Min6 cells were starved for 15, 30, 60 and 120 minutes in HBSS with 0.2% BSA fatty acids free and lysed in immunoprecipitation buffer (2% CHAPS, 50 mM HEPES pH 7.5, 200 mM NaCl, 2 mM EDTA) containing a cocktail of proteinase inhibitor (1:100, Sigma, P8340) for 20 minutes on ice. The lysates were cleared by centrifugation for 30 min at 14000 rpm and 4° C. Approximately 500 ug whole cell lysates was incubated with an IGFR-like receptor SEQ ID No 2 antibody generated in rat and diluted 1:10 for 1 h at 4° C. followed by an incubation with protein G Sepharose 4 Fast Flow (GE Healthcare) for 16 h at 4° C. The precipitates were washed 5 times with immunoprecipitation buffer, denatured at 95° C. for 5 min in 2×SDS sample buffer (100 mM Tris-HCL, 4% SDS, 20% glycerol, 0.2% bromphenol blue) containing 100 mM DTT and 5% 2-mercaptoethanol and subjected to Western blot analysis.
Min6 cells were incubated with 2 mM EZ-Link® Sulfo-NHS-LC-Biotin (Thermo Scientific) in PBS pH 8.0 for 10 min at room temperature after which the biotinylation reaction was stopped with 100 mM glycine in PBS. The cells were then washed in ice cold PBS and lysed in RIPA buffer containing a cocktail of proteinase inhibitor. After clearing by centrifugation at 14000 rpm and 4° C. for 30 minutes the supernatants were incubated overnight at 4° C. with NeutrAvidin beads (Thermo Scientific/Pierce). The next day, after washing 5 times in RIPA buffer, the biotin labeled proteins were eluted from the beads by boiling in 2×SDS sample buffer containing 100 mM DTT and 5% 2-mercaptoethanol and subjected to Western blot analysis.
| Number | Date | Country | Kind |
|---|---|---|---|
| 17153782.2 | Jan 2017 | EP | regional |
| 100143 | Mar 2017 | LU | national |
This continuation-in-part application claims priority to continuation-in-part U.S. application Ser. No. 17/412,066, filed Aug. 25, 2021, which claims priority to U.S. National Stage application Ser. No. 16/481,781, filed Jul. 29, 2019, which in turn claims priority to International Application No. PCT/EP2018/052267, filed Jan. 30, 2018, which claims the benefit of European Patent Application Serial Number 17153782.2, filed Jan. 30, 2017, and Luxembourg Application Serial Number 100143, filed Mar. 16, 2017, wherein said applications are incorporated herein by reference in their entireties.
| Number | Date | Country | |
|---|---|---|---|
| Parent | 17412066 | Aug 2021 | US |
| Child | 18732355 | US | |
| Parent | 16481781 | Jul 2019 | US |
| Child | 17412066 | US |
